

## **PA Criteria**

<b>Prior Authorization Group</b>	ACITRETIN
<b>Drug Names</b>	ACITRETIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have severe disease. Must have adequate trial of methotrexate or cyclosporine with inadequate response or significant side effect/toxicity or have a contraindication to these therapies.
<b>Age Restrictions</b>	Age 18 years or older.
<b>Prescriber Restrictions</b>	Dermatologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	ACNE PRODUCTS
<b>Drug Names</b>	ADAPALENE, AVITA, TAZAROTENE, TAZORAC, TRETINOIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Diagnoses not covered: solar elastosis, sun damage, wrinkles, actinic damage, melasma, lentiginos / freckles (hyperpigmented macules, liver spots), heliodermatitis, dermatoheliosis
<b>Required Medical Information</b>	Diagnosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ACTHAR
<b>Drug Names</b>	H.P. ACTHAR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For infantile spasms: EEG confirming diagnosis of infantile spasms. For following diagnoses where IV steroid trial(s) required: examples include methylprednisolone acetate, methylprednisolone sodium succinate, and triamcinolone acetonide, all of which have FDA-approval for use in these diagnoses. For MS: must be experiencing acute exacerbation of MS and have adequate trial of 2 IV steroids w/ inadequate response or significant side effects/toxicity. For severe erythema multiforme (Stevens-Johnsons Syndrome), serum sickness, severe acute or chronic allergic or inflammatory processes involving eye and its adnexa (e.g. keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation), symptomatic sarcoidosis: must have adequate trial of 2 IV steroids w/ inadequate response or significant side effects/toxicity. For RA (incl. Juvenile RA), psoriatic arthritis, ankylosing spondylitis: must be using as adjunctive therapy for short-term administration (to tide over an acute episode or exacerbation) and have adequate trial of 2 IV steroids w/ inadequate response or significant side effects/toxicity. For systemic lupus erythematosus, dermatomyositis (polymyositis): may be used during exacerbation or as maintenance therapy and must have adequate trial of 2 IV steroids w/ inadequate response or significant side effects/toxicity. For nephrotic syndrome: must be used to induce diuresis or remission of proteinuria, must be experiencing acute exacerbation of nephrotic syndrome, must have adequate trial of 1 IV steroid w/ inadequate response or significant side effect/toxicity AND 1 cytotoxic/immunosuppressive medication (e.g. cyclophosphamide, cyclosporine, mycophenolate) w/ inadequate response or significant side effect/toxicity unless contraindicated. For reauth: must have documentation from prescriber describing initial response to therapy and need for continuation or retreatment.
<b>Age Restrictions</b>	Infantile spasms: age 2 years or younger. MS: age 18 years or older.
<b>Prescriber Restrictions</b>	Infantile spasm: pediatric neurologist. MS: neurologist. RA, Psoriatic Arthritis, Ankylosing Spondylitis: rheumatologist. Lupus, dermatomyositis: dermatologist or rheumatologist. Eye dx: ophthalmologist. Nephrotic syndrome: nephrologist. All other dx: no prescriber restrictions.
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	Not Applicable

**Prior Authorization Group** ACTIMMUNE - PENDING CMS REVIEW  
**Drug Names** ACTIMMUNE  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** ACUTE HAE  
**Drug Names** BERINERT, FIRAZYR, RUCONEST  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis of HAE confirmed by following laboratory values on 2 separate instances (copy of laboratory reports required, must include reference ranges): low C4 complement level in mg/dL, normal C1q complement component level in mg/dL (C1q complement component level not required for patients under age of 18 or patients whose symptoms began before age 18), and either low C1 esterase inhibitor antigenic level in mg/dL or low C1 esterase inhibitor functional level expressed as a percent. Must have chart documentation indicating member has received at least one dose of requested product as treatment for HAE attack in past, responded to medication, and was able to tolerate medication. For reauth, must have documentation from prescriber indicating improvement in condition.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** By or under the direction of a HAE specialist (defined as an allergist/immunologist who attests to clinical experience in HAE).  
**Coverage Duration** Initial: 90 days. Reauth: 365 days.  
**Other Criteria** If clinical documentation confirms the required criteria, Firazyr will be approved after consultation with a Medical Director.

<b>Prior Authorization Group</b>	ADAGEN
<b>Drug Names</b>	ADAGEN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have failed or not be a candidate for bone marrow transplantation. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or less
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ADCIRCA
<b>Drug Names</b>	ADCIRCA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Current use of nitrate product
<b>Required Medical Information</b>	Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have WHO Functional Class II-IV symptoms. Must have inadequate response or intolerance to sildenafil (Revatio). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

**Prior Authorization Group**

**Drug Names**

**Covered Uses**

**Exclusion Criteria**

**Required Medical Information**

ADEFOVIR

ADEFOVIR DIPIVOXIL

All FDA-approved indications not otherwise excluded from Part D

Hepatitis B Virus Drug Resistance panel showing resistance to prior tx w/ adefovir Diagnosis. Must have documentation of results of Hep B Virus Drug Resistance panel if previously received antiviral tx regimen for Hep B. Must have documentation of baseline eval and results for following tests: Hep B virus (HBV) DNA viral load, hepatitis B e antigen (HBeAg), antibody to hepatitis B e antigen (anti-HBe), hepatitis B surface antigen (HBsAg), antibody to hepatitis surface antigen (anti-HBs), liver biopsy (if available), alanine aminotransferase (ALT) level and assay reference range. Must have an adequate trial of entecavir with inadequate response, significant side effect/toxicity, contraindication, or documented viral resistance to entecavir or have clinical rationale to support use of adefovir over entecavir. For reauth: must have doc from prescriber indicating continued benefit from tx, doc of recent HBV DNA level, chart doc of HBV Drug Resistance panel if mbr has evidence of virologic breakthrough (greater than 10-fold increase in serum HBV DNA from nadir during tx in mbr who had initial virologic response), and doc of HBeAg/Anti-HBe/HBsAg/Anti-HBs (for mbrs with HBeAg positive and for mbrs with HBeAg negative not falling under any other indications).

No Age Restrictions

**Age Restrictions**

**Prescriber Restrictions**

Infectious disease physician, gastroenterologist, hepatologist, or transplant physician

**Coverage Duration**

365 days or until disease progression or clearance

**Other Criteria**

Regimens/requirements based upon AASLD Practice Guidelines for Chronic Hepatitis B. For HBeAg+ chronic HBV: must meet 1 ALT criterion (ALT greater than or equal to 2xULN OR evidence of moderate/severe inflammation or signif. fibrosis on biopsy) and have HBV DNA level greater than 20,000 IU/mL (not required for pediatric patients if ALT greater than or equal to 2xULN for longer than 6 months). For HBeAg- chronic HBV: must meet 1 ALT criterion (ALT greater than or equal to 2xULN, ALT greater than 1xULN w/ evidence of moderate/severe inflammation or signif. fibrosis on biopsy, ALT less than or equal to ULN w/ ALT increased over time) and 1 HBV DNA criterion (HBV DNA greater than 20,000 IU/mL, HBV DNA greater than 2,000 IU/mL w/ evidence of moderate/severe inflammation or signif. fibrosis on biopsy, HBV DNA less than or equal to 2,000 IU/mL w/ HBV DNA increased over time). For cirrhosis w/ HBV: must have HBV DNA greater than 2,000 IU/mL OR detectable HBV DNA level w/ elevated ALT. For HBV mbr who had liver txfr for HBV or who received solid organ txfr from HBV+ donor: approve regardless of HBV DNA and ALT levels. For HBV carrier who needs immunosuppressive or cytotoxic tx: must be HBsAg+, have planned course of cancer chemotx or immunosuppressive tx. Reauth for HBeAg+: approve x1 year until all of following are met (loss of HBeAg, undetectable serum HBV DNA, completed 6-12 months of additional tx after appearance of anti-HBe. Reauth for HBeAg-: approve x1 yr until loss of HBsAg. Reauth for cirrhosis, for liver txfr for HBV, or for solid organ txfr from HBV+ donor: long-term tx approvable. Reauth for HBV carriers receiving immunosuppressive or cytotoxic tx: mbr w/ baseline HBV DNA less than 2,000 IU/mL should continue x6 months after completion of chemotx or immunosuppressive tx, mbr

w/ baseline HBV DNA greater than 2,000 IU/mL should continue until reach therapeutic endpoints for immunocompetant HBV as listed above.

<b>Prior Authorization Group</b>	ADEMPAS
<b>Drug Names</b>	ADEMPAS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Current use of nitrate product or phosphodiesterase inhibitor (i.e. sildenafil or tadalafil).
<b>Required Medical Information</b>	Diagnosis. Must have baseline negative pregnancy test prior to initiation of riociguat (if a female of childbearing potential). For PAH (WHO Group I), must have diagnosis confirmed by right heart catheterization, must have inadequate response or intolerance to sildenafil (Revatio), AND must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. For reauth: must have chart documentation from prescriber indicating improvement in condition. For CTEPH (WHO Group 4), must be refractory to surgical treatment (i.e. pulmonary endarterectomy) or have inoperable CTEPH, must have chart documentation showing CTEPH confirmed through ventilation-perfusion scanning or pulmonary angiography AND a right heart catheterization that indicates the following hemodynamic values at least 90 days after start of full anticoagulation or 180 days after pulmonary endarterectomy unless there is clinical evidence of right heart failure and pulmonary hypertension on clinical exam and echocardiogram: mean pulmonary arterial pressure greater than 25mmHg and pulmonary vascular resistance greater than 3 Wood units. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	AFINITOR
<b>Drug Names</b>	AFINITOR, AFINITOR DISPERZ
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ALDURAZYME
<b>Drug Names</b>	ALDURAZYME
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 6 months or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ALECENSA
<b>Drug Names</b>	ALECENSA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming ALK mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ALOSETRON
<b>Drug Names</b>	ALOSETRON HYDROCHLORIDE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Male gender. Constipation. Anatomical or biochemical abnormalities of the gastrointestinal tract. Concomitant use of fluvoxamine. History of chronic or severe constipation or sequelae from constipation, intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state, Crohn's disease or ulcerative colitis, diverticulitis, severe hepatic impairment.
<b>Required Medical Information</b>	Diagnosis. Must have chronic IBS symptoms. Must have chart documentation of how diagnosis was confirmed. Must have adequate trial of loperamide AND an antispasmodic (e.g. dicyclomine) with inadequate response or significant side effect/toxicity or have a contraindication. For reauth: must have documentation from prescriber indicating improvement in condition and no evidence of constipation or ischemic colitis.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Gastroenterologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ALPHA1-PROTEINASE INHIBITORS
<b>Drug Names</b>	ARALAST NP, GLASSIA, PROLASTIN-C, ZEMAIRA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Confirmed diagnosis of congenital alpha1-antitrypsin deficiency with clinically evident emphysema or airflow obstruction. Alpha1-antitrypsin phenotype of PI*ZZ, PI*ZNull or PI*NullNull. Baseline (pretreatment) serum alpha1-antitrypsin concentration of less than 11 micromol/L as documented by either of the following: less than 50mg/dL as determined by nephelometry OR less than 80mg/dL as determined by radial immunodiffusion. Must not have selective IgA deficiencies with known antibodies against IgA (anti-IgA antibodies). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a pulmonologist
<b>Coverage Duration</b>	365 Days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ALUNBRIG
<b>Drug Names</b>	ALUNBRIG
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming ALK mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	AMPYRA
<b>Drug Names</b>	AMPYRA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Moderate to severe renal impairment (CrCl less than or equal to 50mL/min), history of seizure, on concomitant therapy with other forms of 4-aminopyridine.
<b>Required Medical Information</b>	Diagnosis. Chart documentation of baseline motor disability or dysfunction. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Neurologist or Physical Medicine and Rehabilitation physician in consultation with the member's treating Neurologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	ANADROL
<b>Drug Names</b>	ANADROL-50
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Carcinoma of breast or prostate in male patients. Carcinoma of breast in female patients with hypercalcemia. Pregnancy. Nephrosis (i.e. nephrotic phase of nephritis). Severe hepatic dysfunction.
<b>Required Medical Information</b>	Diagnosis. Anemia must be due to deficient red cell production (e.g. acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, hypoplastic anemia). For reauth: must have documentation from prescriber indicating improvement or stabilization in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Hematologist or oncologist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	ANDROGENS
<b>Drug Names</b>	ANDRODERM, METHYLTESTOSTERONE, STRIANT, TESTOSTERONE, TESTOSTERONE CYPIONATE, TESTOSTERONE ENANTHATE, TESTOSTERONE PUMP
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D. For methyltestosterone, treatment of females with inoperable breast cancer is covered.
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	APOKYN
<b>Drug Names</b>	APOKYN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Concomitant therapy with 5-HT3 antagonist (e.g. ondansetron)
<b>Required Medical Information</b>	Diagnosis. Must be on concomitant therapy with carbidopa/levodopa AND one of the following numbered options: (1)a dopamine agonist (e.g. ropinirole or pramipexole), (2)a monoamine oxidase-B inhibitor (e.g. rasagiline or selegiline), or (3)a catechol O-methyltransferase inhibitor (e.g. entacapone). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	APTiom
<b>Drug Names</b>	APTiom
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have had an inadequate response or intolerance to 2 generic antiepileptic drugs (e.g., oxcarbazepine, carbamazepine, lamotrigine, valproic acid, levetiracetam, zonisamide). If using eslicarbazepine as adjunctive therapy to other antiepileptic drugs, cannot be used with oxcarbazepine. Must have documentation of baseline transaminase and bilirubin levels.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a neurologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ARANESP
<b>Drug Names</b>	ARANESP ALBUMIN FREE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Uncontrolled hypertension, known hypersensitivity to active substance or any excipients of product.
<b>Required Medical Information</b>	Diagnosis. Must have Hgb less than 10g/dL. For anemia due to chemotx for nonmyeloid malignancy: must have documentation of a minimum of 2 more months of chemotx planned. All dx: Must have iron status evaluated before and during treatment with EPO. Reauth for CKD on dialysis: must have Hgb less than 11g/dL. Reauth for CKD not on dialysis: must have Hgb less than 10g/dL. Reauth for anemia due to chemotx for nonmyeloid malignancy: must have Hgb less than 12g/dL and documentation of a minimum 2 more months of chemotx planned. Reauth for other dx: must have Hgb less than 12g/dL.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a nephrologist, hematologist/oncologist, or transplant physician
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 90 days for chemotx, 180 days for other dx.
<b>Other Criteria</b>	Part B versus Part D determination will made at time of prior authorization review per CMS guidance to establish if the drug prescribed is to be used for an ESRD-related condition. If the drug is determined not to be ESRD-related, criteria apply.

<b>Prior Authorization Group</b>	ARCALYST
<b>Drug Names</b>	ARCALYST
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. Use of TNF-blocking or other biologic agent in combination with rilonacept.
<b>Required Medical Information</b>	Diagnosis. Negative tuberculosis skin test, baseline lipid panel assessment. For Muckle-Wells: must have chart doc of diagnosis confirmed by genetic test (must have documentation of lab result confirming mutation in NLRP3 gene) or a clinical diagnosis (must have 3 of following: autosomal dominant pattern of disease inheritance, presence of severe fatigue, presence of musculoskeletal symptoms, presence of ocular symptoms, presence of erythematous rash, duration of most febrile episodes lasting greater than 24 hours, presence of amyloidosis, presence of hearing loss). For Familial Cold Autoinflammatory Syndrome: must have chart doc of diagnosis confirmed by genetic test (must have documentation of lab result confirming mutation in NLRP3 gene) or a clinical diagnosis (must have 4 of following: recurrent intermittent episodes of fever and rash that primarily follow natural/experimental/both types of generalized cold exposures, autosomal dominant pattern of disease inheritance, age of onset less than 6 months of age, duration of most attacks less than 24 hours, presence of conjunctivitis associated with attacks, absence of deafness/periorbital edema/lymphadenopathy/serositis). For reauth: must have documentation from prescriber indicating improvement in condition and assessment of lipid panel within 3 months (1st reauth) and regularly thereafter.
<b>Age Restrictions</b>	Age 12 years or older
<b>Prescriber Restrictions</b>	Rheumatologist, dermatologist, immunologist, or genetic specialist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	ARIPIPRAZOLE
<b>Drug Names</b>	ARIPIPRAZOLE, ARIPIPRAZOLE ODT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For Major Depressive Disorder without psychosis, must have adequate trial and failure or inadequate response, duration of at least 4 weeks, or intolerance to monotherapy with 2 different antidepressant therapies (e.g. SSRIs or SNRIs) and must be on concomitant therapy with an SSRI or SNRI as adjunctive treatment (which can include medication from monotherapy trial above)
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	ARMODAFANIL
<b><i>Drug Names</i></b>	ARMODAFINIL
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. Must have chart documentation of sleep study confirming diagnosis for narcolepsy and OSA. Must have adequate trial of modafinil with an inadequate response OR have had a significant side effect/toxicity to modafinil. For narcolepsy: must have adequate trial and failure of CNS stimulant (e.g. amphetamine salts, dextroamphetamine, methylphenidate). For shift-work sleep disorder (SWSD), must meet International Classification of Sleep Disorders criteria for SWSD (either primary complaint of excessive sleepiness or insomnia temporarily associated w/ work period that occurs during habitual sleep phase OR polysomnography and Multiple Sleep Latency Test demonstrate loss of normal sleep-wake pattern, no other medical or mental disorders account for symptoms, and symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness such as time zone change syndrome) and must provide chart documentation of shift work schedule showing 5 or more night shifts per month (defined as at least 4 hours of shift occurring between 10pm and 8am). For reauth: must have documentation from prescriber indicating improvement in condition.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	No Prescriber Restrictions
<b><i>Coverage Duration</i></b>	SWSD: 180 days. Narcolepsy, OSA: 365 days.
<b><i>Other Criteria</i></b>	Not Applicable

**Prior Authorization Group**

**Drug Names**

B VS. D

ABELCET, ACETYLCYSTEINE, ACYCLOVIR SODIUM, ADRUCIL, ALBUTEROL SULFATE, AMBISOME, AMINOSYN 7%/ELECTROLYTES, AMINOSYN 8.5%/ELECTROLYTE, AMINOSYN II, AMINOSYN II 8.5%/ELECTROL, AMINOSYN M, AMINOSYN-HBC, AMINOSYN-PF, AMINOSYN-PF 7%, AMINOSYN-RF, AMIODARONE HCL, AMPHOTERICIN B, APREPITANT, ARZERRA, ATGAM, AZATHIOPRINE, BETHKIS, BLEOMYCIN SULFATE, BROVANA, BUDESONIDE, CANCIDAS, CELLCEPT INTRAVENOUS, CIDOFOVIR, CLADRIBINE, CLINIMIX 2.75%/DEXTROSE 5, CLINIMIX 4.25%/DEXTROSE 1, CLINIMIX 4.25%/DEXTROSE 2, CLINIMIX 4.25%/DEXTROSE 5, CLINIMIX 5%/DEXTROSE 15%, CLINIMIX 5%/DEXTROSE 20%, CLINIMIX 5%/DEXTROSE 25%, CLINIMIX E 2.75%/DEXTROSE, CLINIMIX E 4.25%/DEXTROSE, CLINIMIX E 5%/DEXTROSE 15, CLINIMIX E 5%/DEXTROSE 20, CLINIMIX E 5%/DEXTROSE 25, CLINISOL SF 15%, CLONIDINE HCL, CROMOLYN SODIUM, CYCLOPHOSPHAMIDE, CYCLOSPORINE, CYCLOSPORINE MODIFIED, CYRAMZA, CYTARABINE AQUEOUS, EMEND, EMLICITI, ENGERIX-B, EPOPROSTENOL SODIUM, FLUOROURACIL, FOSCARNET SODIUM, FREAMINE HBC 6.9%, GABLOFEN, GANCICLOVIR, GENGRAF, GRANISETRON HCL, HEPATAMINE, INTRALIPID, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE/ALBUT, KABIVEN, LEVALBUTEROL, LEVALBUTEROL HCL, LIORESAL INTRATHECAL, METHOTREXATE SODIUM, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID DR, NEBUPENT, NEPHRAMINE, NITROGLYCERIN, ONDANSETRON HCL, ONDANSETRON ODT, PERFOROMIST, PERIKABIVEN, PLENAMINE, PORTRAZZA, PREMASOL, PROCALAMINE, PROGRAF, PROSOL, RECOMBIVAX HB, SENSIPAR, SIMULECT, TACROLIMUS, THYMOGLOBULIN, TOBRAMYCIN, TRAVASOL, TROPHAMINE, VECTIBIX, VELETRI, VINBLASTINE SULFATE, VINCASAR PFS, VINCRISTINE SULFATE

**Covered Uses**

NA

**Exclusion Criteria**

**Required Medical Information**

**Age Restrictions**

**Prescriber Restrictions**

**Coverage Duration**

NA

**Other Criteria**

<b>Prior Authorization Group</b>	BANZEL
<b>Drug Names</b>	BANZEL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Lennox-Gastaut Syndrome. Must have had an inadequate response or intolerance to 2 generic antiepileptic drugs (e.g. lamotrigine, topiramate, felbamate) and be using rufinamide as adjunctive therapy to other antiepileptic drugs (which can include medication from trial above).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a neurologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	BARBITURATES
<b>Drug Names</b>	PHENOBARBITAL, PHENOBARBITAL SODIUM
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	BAVENCIO
<b>Drug Names</b>	BAVENCIO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Age 12 years or older
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	BENLYSTA
<b>Drug Names</b>	BENLYSTA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Severe active lupus nephritis or severe active central nervous system lupus. Evidence of infection. On concomitant therapy with biologic therapies, including B-cell targeted therapies, or IV cyclophosphamide.
<b>Required Medical Information</b>	Diagnosis of systemic lupus erythematosus. Must be auto-antibody positive, as evidenced through documentation of having one of the following laboratory markers: positive antinuclear antibodies titer greater than or equal to 1:80 or anti-double stranded DNA greater than or equal to 30 IU/mL. Must have adequate trial of hydroxychloroquine, azathioprine, methotrexate, or mycophenolate with inadequate response or significant side effect/toxicity or have a contraindication to these therapies. Must be on concomitant therapy with any of the following (alone or in combination): corticosteroids, antimalarials, NSAIDs, and/or immunosuppressants. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Rheumatologist
<b>Coverage Duration</b>	Initial 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	BOSULIF
<b>Drug Names</b>	BOSULIF
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	BOTOX - PENDING CMS REVIEW
<b>Drug Names</b>	BOTOX
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	



<b>Prior Authorization Group</b>	BRIVIACT
<b>Drug Names</b>	BRIVIACT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have had an inadequate response or intolerance to two other antiepileptic drugs. Must have an evaluation by a psychiatrist and be followed concurrently by a psychiatrist if the member has a history of psychiatric symptoms including anger, aggression, hostility, irritability, suicidal ideation, and homicidal ideation OR if the member is currently undergoing psychiatric treatment. Must be using as adjunctive therapy to other anti-epileptic medications (which can include medications from trials above).
<b>Age Restrictions</b>	Age 16 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a neurologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CABOMETRYX
<b>Drug Names</b>	CABOMETRYX
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have documentation of prior anti-angiogenic therapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with an oncologist or hematologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CAPRELSA
<b>Drug Names</b>	CAPRELSA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CARBAGLU
<b>Drug Names</b>	CARBAGLU
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Confirmed diagnosis of one of the following deficiencies: N-acetylglutamate synthase (NAGS), N-acetylglutamate (NAG), or carbamoyl phosphate synthetase 1 (CPS 1). Must have chart documentation describing how diagnosis was confirmed (e.g. genetic testing results, enzyme assays, ammonia levels, progress notes, etc.). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a physician who specializes in the treatment of inherited metabolic disorders.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CERDELGA
<b>Drug Names</b>	CERDELGA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	On concomitant therapy with a CYP2D6 inhibitor (e.g. paroxetine) and a strong or moderate CYP3A inhibitor (e.g. ketoconazole) if a CYP2D6 extensive or intermediate metabolizer. On concomitant therapy with a strong CYP3A inhibitor (e.g. ketoconazole) if a CYP2D6 intermediate or poor metabolizer. CYP2D6 ultra-rapid metabolizer.
<b>Required Medical Information</b>	Diagnosis of mild to moderate Type I Gaucher disease with any of the following: hepatomegaly (defined as liver size greater than or equal to 1.25 times normal), splenomegaly (defined as spleen size greater than 0.2% of body weight), bone disease (defined as having one of the following: avascular necrosis, erlenmeyer flask deformity, lytic disease, marrow infiltrations, osteopenia, osteosclerosis, pathological fracture, or radiological evidence of joint deterioration), or bone marrow disease (defined as having anemia or thrombocytopenia). Must not have enzyme replacement therapy as therapeutic option (e.g. allergy/hypersensitivity to ERT, poor venous access, difficulties w/ infusion). Must have chart documentation of FDA-cleared test confirming CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM). For reauth: must have documentation from prescriber indicating improvement in condition and that member is being monitored for neurological side effects of Cerdelga.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	CHEMET
<b><i>Drug Names</i></b>	CHEMET
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. Must have blood lead level greater than 45 micrograms per deciliter. Must have chart documentation of identification and removal of the cause of lead exposure. For reauth: must meet initial authorization criteria and have clinical rationale from the prescriber for continuation of treatment.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	Toxicologist or other clinician who has experience with chelating agents
<b><i>Coverage Duration</i></b>	30 days
<b><i>Other Criteria</i></b>	Not Applicable

<b>Prior Authorization Group</b>	CINRYZE
<b>Drug Names</b>	CINRYZE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of HAE and confirmatory laboratory values on 2 separate instances (copy of laboratory reports required, must include reference ranges). For Type I: low C4 complement level in mg/dL, normal C1q complement component level in mg/dL (C1q complement component level not required for patients under age of 18 or patients whose symptoms began before age 18), and either low C1 esterase inhibitor antigenic level in mg/dL or low C1 esterase inhibitor functional level expressed as a percent. For Type II: low C4 complement level in mg/dL, normal C1q complement component level in mg/dL (C1q complement component level not required for patients under age of 18 or patients whose symptoms began before age 18), and low C1 esterase inhibitor functional level expressed as a percent. For Type III: chart documentation of exclusion of other possible diagnoses and/or causes of angioedema. For all types, must have chart documentation of each previous HAE attack to demonstrate member is candidate for prophylactic therapy to include one of the following: history of frequent HAE attacks (defined as 2 or more HAE attacks per month) or history of severe HAE attacks (defined as 1 or more abdominal attack in past 12 months or any attack of respiratory tract which compromised airway). Must have had trial and failure of, intolerance to, or contraindication to an attenuated androgen (e.g. danazol, stanozolol, oxandrolone). For reauth, must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 9 years or older
<b>Prescriber Restrictions</b>	By or under the direction of a HAE specialist (defined as an allergist/immunologist who attests to clinical experience in HAE).
<b>Coverage Duration</b>	Initial: 120 days. Reauth: 365 days.
<b>Other Criteria</b>	Must be used as prophylactic therapy for prevention of HAE attacks. If clinical documentation confirms the required criteria, C1 inhibitor [human] will be approved after consultation with a Medical Director.

<b>Prior Authorization Group</b>	CLONIDINE ER
<b>Drug Names</b>	CLONIDINE HCL ER
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Attention Deficit Hyperactivity Disorder. Must have adequate trial and failure of clonidine (non-extended release) with inadequate response or significant side effects/toxicity unless contraindicated. Must have adequate trial of a CNS stimulant (e.g. methylphenidate, amphetamine salts) with inadequate response or significant side effects/toxicity unless contraindicated.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	COMETRIQ
<b>Drug Names</b>	COMETRIQ
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CORLANOR
<b>Drug Names</b>	CORLANOR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Blood pressure less than 90/50mmHg. Current acute decompensated heart failure. Sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present. Severe hepatic impairment. Dependence on a pacemaker, where heart rate is maintained exclusively by the pacemaker, such as ventricular or atrioventricular pacing more than 40% of the day or demand pacemakers set to a rate greater than 60 beats per minute.
<b>Required Medical Information</b>	Diagnosis. Must currently be taking a beta-blocker (e.g., metoprolol succinate sustained-release, carvedilol, bisoprolol) at maximum tolerated dose for heart failure unless a prior trial with beta-blocker therapy resulted in significant side effect/toxicity or there is a contraindication to use of beta-blocker therapy (e.g., bronchospastic disease such as chronic obstructive pulmonary disease and asthma, severe hypotension or bradycardia).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	COTELLIC
<b>Drug Names</b>	COTELLIC
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming BRAFV600E or BRAFV600K mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CYSTAGON
<b>Drug Names</b>	CYSTAGON
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of a clinical work-up to rule out other diagnoses and clinical rationale for the diagnosis and exclusion of other diagnoses. Diagnosis must be confirmed by having all of the following: elevated white blood cell cystine levels greater than 2nmol per 1/2 cystine per mg of protein, laboratory result confirming CTNS gene mutation, and clinical symptoms of nephropathic cystinosis including electrolyte imbalances and polyuria. For reauth: must have documentation from prescriber indicating improvement in condition and a reduction in WBC cystine levels since starting treatment with oral cysteamine.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a nephrologist or physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	CYSTARAN
<b>Drug Names</b>	CYSTARAN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis (dx). Must have chart documentation of a clinical work-up to rule out other dx and clinical rationale for dx and exclusion of other dx. Must have chart documentation of elevated baseline white blood cell (WBC) cystine level greater than 2nmol per 1/2 cystine per mg of protein, laboratory result confirming CTNS gene mutation, clinical symptoms consistent with dx (i.e. photophobia, corneal erosions, keratopathies), AND ophthalmologic exam confirming dx. For reauth: must have documentation from prescriber indicating improvement in condition and indicating evaluation of compliance with therapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with an ophthalmologist or a physician who specializes in the treatment of inherited metabolic disorders.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	DALIRESP
<b>Drug Names</b>	DALIRESP
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Moderate to severe liver impairment.
<b>Required Medical Information</b>	Diagnosis of GOLD Stage III or IV COPD associated with chronic bronchitis. Documentation of COPD exacerbation within the past year. Must have adequate trial and failure of inhaled long-acting beta-agonist or inhaled long-acting anticholinergic or a contraindication to these agents. Must have trial and failure of inhaled glucocorticosteroid or a contraindication to these agents. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	DEPEN
<b>Drug Names</b>	DEPEN TITRATABS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have baseline (within 6 months) urinalysis, complete blood cell count, platelet count, and hemoglobin. For Wilson's disease, must have chart documentation of how diagnosis was confirmed including at least one of the following: hepatic parenchymal copper content greater than or equal to 250 micrograms per gram dry weight, presence of Kayser-Fleischer Ring in cornea, serum ceruloplasmin level less than 50mg/L, basal 24-hour urinary excretion of copper greater than 100 micrograms (1.6 millimoles), or genetic testing indicating mutation in ATP7B gene. For Cystinuria: must have chart documentation of how diagnosis was confirmed. For Rheumatoid Arthritis: must have severely active disease, must have an adequate trial of methotrexate with inadequate response or significant side effects or toxicity or have a contraindication, and must have an adequate trial of leflunomide, hydroxychloroquine, minocycline, or sulfasalazine with inadequate response or significant side effects or toxicity or have a contraindication. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Wilson's disease, cystinuria: by or in consultation with physician who specializes in the treatment of inherited metabolic disorders. RA: rheumatologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	DRONABINOL
<b>Drug Names</b>	DRONABINOL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For chemotherapy induced nausea and vomiting, patient must be receiving chemotherapy. For AIDS anorexia, patient must have diagnosis of AIDS with anorexia and weight loss. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist, gastroenterologist, or infectious disease physician
<b>Coverage Duration</b>	180 days
<b>Other Criteria</b>	B vs. D determination will be made prior to clinical criteria being applied.
<b>Prior Authorization Group</b>	DUAVEE
<b>Drug Names</b>	DUAVEE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Undiagnosed abnormal uterine bleeding. Known, suspected, or past history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active or past history of venous thromboembolism and/or arterial thromboembolism. Known hepatic impairment or disease. Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders. Pregnancy, women who may become pregnant, and nursing mothers.
<b>Required Medical Information</b>	Diagnosis. For moderate to severe vasomotor symptoms associated with menopause: must have documentation of clinical rationale for continued use of Duavee (including an explanation of the member's specific benefit of the drug and how that benefit outweighs the potential risk), documentation demonstrating return of significant vasomotor symptoms when withdrawal of estrogen therapy is tried, AND documentation of previous adequate trial of Femring with an inadequate response or significant side effect/toxicity. For osteoporosis prophylaxis: must have adequate trials with a bisphosphonate (e.g. alendronate) and raloxifene with inadequate responses or significant side effects/toxicities unless contraindicated. For vasomotor symptom reauth: must have documentation of clinical rationale for continued use of Duavee (including an explanation of the member's specific benefit of the drug and how that benefit outweighs the potential risk) and documentation demonstrating trial of Duavee withdrawal with return of significant vasomotor symptoms. For osteoporosis reauth: must have documentation indicating continued benefit with use of Duavee.
<b>Age Restrictions</b>	Age 65 years or older: criteria apply. Age less than 65 years: criteria do not apply.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	DUOPA
<b>Drug Names</b>	DUOPA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Must have a diagnosis of advanced Parkinson's disease including the following: a clear motor response to levodopa in the trial below, chart documentation of the Hoehn and Yahr stage or Unified Parkinson's Disease Rating Scale (UPDRS) part III motor subscale, and chart documentation of motor fluctuations including either or both: initial benefit after dose of levodopa in the trial below followed by return of parkinsonian features before onset of benefit from subsequent dose (e.g. wearing off) and/or evidence of involuntary movements when therapeutic effect of levodopa in the trial below is maximal (e.g. peak dose dyskinesia). Must have an adequate trial of concomitant therapy with carbidopa/levodopa and a dopamine agonist (e.g. pramipexole) with an inadequate response, despite modification in levodopa dosage, or significant side effects/toxicity or have a contraindication to a therapy. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	B vs. D determination will be made prior to clinical criteria being applied.

<b>Prior Authorization Group</b>	DYSPORT
<b>Drug Names</b>	DYSPORT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	EGRIFTA
<b>Drug Names</b>	EGRIFTA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Active malignancy, history of malignancy, pregnant female, or disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma
<b>Required Medical Information</b>	Diagnosis of lipodystrophy with excess abdominal fat and underlying diagnosis of HIV infection. Must be stable on an antiretroviral regimen for at least 8 weeks prior to beginning tesamorelin. Must have waist circumference of at least 95cm (37.4in) and a waist to hip ratio of at least 0.94 for males OR waist circumference of at least 94cm (37in) and a waist to hip ratio of at least 0.88 for females. Must have baseline (within past 6 months) evaluation of fasting blood glucose and IGF-1. Must have baseline negative pregnancy test prior to initiation of therapy if member is a woman of childbearing potential. For reauth: must have documentation showing decreases from baseline in both waist circumference and waist to hip ratio, no active malignancy or history of malignancy, and showing fasting blood glucose and IGF-1 levels are being monitored.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with an endocrinologist or physician who specializes in the treatment of HIV/AIDS
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	ELAPRASE
<b>Drug Names</b>	ELAPRASE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Confirmed diagnosis of Hunter Syndrome (mucopolysaccharidosis type II).
<b>Age Restrictions</b>	Age 16 months or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ELIDEL AND TOPICAL TACROLIMUS
<b>Drug Names</b>	ELIDEL, TACROLIMUS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Weakened or compromised immune system
<b>Required Medical Information</b>	Diagnosis. For topical tacrolimus: must have adequate trial and failure of moderate to high potency topical corticosteroid or have a contraindication to this therapy (such as dermatitis on face, genitalia). For pimecrolimus (Elidel): must have adequate trial and failure of moderate to high potency topical corticosteroid or have a contraindication to this therapy (such as dermatitis on face, genitalia) AND must have adequate trial and failure of topical tacrolimus with inadequate response or significant side effect/toxicity or have a contraindication to this therapy. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Elidel, tacrolimus 0.03%: age 2 years or older. Tacrolimus 0.1%: age 16 years or older.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	EMCYT
<b>Drug Names</b>	EMCYT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ENBREL
<b>Drug Names</b>	ENBREL, ENBREL SURECLICK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. Use of TNF-blocking or other biologic agent in combination with etanercept.
<b>Required Medical Information</b>	Diagnosis. Negative tuberculosis skin test. For RA and JIA: must have diagnosis of moderately to severely active disease, must have adequate trial of methotrexate with inadequate response (if significant side effects/toxicity or contraindication to methotrexate must have adequate trial of hydroxychloroquine, leflunomide, or sulfasalazine for RA and of leflunomide or sulfasalazine for JIA). For psoriatic arthritis (peripheral disease): must have moderately to severely active psoriatic arthritis AND must have adequate trial of 1 NSAID at target anti-inflammatory dose and of 1 conventional systemic therapy (e.g. methotrexate, cyclosporine, leflunomide, sulfasalazine) with inadequate responses or significant side effects/toxicities or have contraindication to these therapies. For psoriatic arthritis (axial, skin, nail, enthesitis, or dactylitis dominant): must have an adequate trial of 2 NSAIDs at target anti-inflammatory dose with inadequate response or sig. side effects/toxicities unless contraindicated. For ankylosing spondylitis: must have active disease and must have adequate trial of 2 NSAID at target anti-inflammatory dose with inadequate response or significant side effects/toxicity or have a contraindication. For plaque psoriasis: must have chronic moderate to severe plaque psoriasis, must have minimum BSA involvement of at least 5% (not required if plaque psoriasis on palms, soles, head/neck, or genitalia), must have adequate trial of 1 topical treatment or phototherapy or photochemotherapy with inadequate response or significant side effects/toxicity or have a contraindication, and must have adequate trial of 1 conventional systemic therapy (e.g. methotrexate, acitretin, cyclosporine) with inadequate response or significant side effects/toxicity or have a contraindication. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	RA, JIA, ankylosing spondylitis: rheumatologist. Psoriatic arthritis: rheumatologist or dermatologist. Plaque psoriasis: dermatologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

**Prior Authorization Group** ENTECAVIR - PENDING CMS REVIEW  
**Drug Names** BARACLUDE, ENTECAVIR  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** EPOGEN AND PROCRIT  
**Drug Names** EPOGEN, PROCRIT  
**Covered Uses** All medically accepted indications not otherwise excluded from Part D  
**Exclusion Criteria** Uncontrolled hypertension, known hypersensitivity to active substance or any excipients of product.  
**Required Medical Information** Diagnosis. Initial for ribavirin-induced anemia: must have Hgb less than 10g/dL or a 3g/dL decrease from baseline with anemia symptoms and documentation that dose reduction of ribavirin did not resolve anemia. Initial to reduce risk of allogenic blood transfusions: must have Hgb 10-13g/dL and be at high risk for perioperative transfusion due to significant anticipated blood loss and be scheduled to undergo elective, non-cardiac, or nonvascular surgery. Initial for other dx: must have Hgb less than 10g/dL. Initial for anemia due to chemotx for nonmyeloid malignancy: must have documentation of a minimum 2 more months of chemotx planned. Must have iron status evaluated before and during treatment with EPO. Reauth for CKD on dialysis: must have Hgb less than 11g/dL. Reauth for CKD not on dialysis: must have Hgb less than 10g/dL. Reauth for pediatric CKD: must have Hgb less than 12 g/dL. Reauth for anemia due to chemotx for nonmyeloid malignancy: must have Hgb less than 10g/dL and documentation of a minimum 2 more months of chemotx planned. Reauth for other dx: must have Hgb less than 12g/dL.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** By or in consultation with a nephrologist, hematologist/oncologist, gastroenterologist, hepatologist, transplant physician, surgeon, or an infectious disease physician  
**Coverage Duration** Initial: 90 days. Reauth: 90 days for d/t chemotx, 180 days for other dx.  
**Other Criteria** Part B versus Part D determination will made at time of prior authorization review per CMS guidance to establish if the drug prescribed is to be used for an ESRD-related condition. If the drug is determined not to be ESRD-related, criteria apply.

<b>Prior Authorization Group</b>	ERIVEDGE
<b>Drug Names</b>	ERIVEDGE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ESBRIET AND OFEV
<b>Drug Names</b>	ESBRIET, OFEV
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have definitive diagnosis of idiopathic pulmonary fibrosis confirmed by either high-resolution computed tomography (HRCT) or surgical lung biopsy. Must have all other diagnoses ruled out (e.g., domestic and occupational environmental exposures, connective tissue disease, and drug toxicity). Must submit documentation of baseline liver function testing, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin. For reauth: must have documentation from prescriber indicating that member still is a candidate for treatment and showing that liver function tests (including ALT, AST, and bilirubin) are being monitored regularly.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 180 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	EUCRISA
<b>Drug Names</b>	EUCRISA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have adequate trial and failure of moderate to high potency topical corticosteroid or have a contraindication to this therapy (such as dermatitis on face, genitalia) AND must have adequate trial and failure of topical tacrolimus with inadequate response or significant side effect/toxicity or have a contraindication to this therapy. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	EXJADE
<b>Drug Names</b>	EXJADE, JADENU, JADENU SPRINKLE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Concomitant advanced malignancy or high-risk myelodysplastic syndrome. Serum creatinine greater than 2 times the age-appropriate upper limit of normal or creatinine clearance less than 40mL/min.
<b>Required Medical Information</b>	Diagnosis. Must have platelet count greater than or equal to 50,000. For treatment of chronic iron overload due to non-transfusion dependent thalassemia syndromes: must have liver iron concentration of at least 5mg of iron per gram dry weight and serum ferritin greater than 300mcg/L. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Due to transfusions: age 2 years or older. Not due to transfusions: age 10 years or older.
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	FABRAZYME
<b>Drug Names</b>	FABRAZYME
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For males: must have diagnosis of Fabry disease based upon clinical symptoms or by genetic testing. For females: must have presumed symptoms of Fabry disease (heterozygous carriers) based on family history and/or genetic testing. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FANAPT
<b>Drug Names</b>	FANAPT, FANAPT TITRATION PACK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have adequate trial and failure of risperidone and 1 other atypical antipsychotic (including, but not limited to: aripiprazole, olanzapine, quetiapine, ziprasidone) with inadequate responses or intolerance.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FARESTON
<b>Drug Names</b>	FARESTON
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have previous inadequate response or intolerance to tamoxifen.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FARYDAK
<b>Drug Names</b>	FARYDAK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FENTANYL CITRATE
<b>Drug Names</b>	ABSTRAL, FENTANYL CITRATE ORAL TRA, FENTORA, LAZANDA, SUBSYS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Treatment of acute or postoperative pain.
<b>Required Medical Information</b>	Diagnosis. Must be opioid tolerant, defined as requiring medication for a week or longer containing at least 60mg/day of morphine. Must currently be using a long-acting opioid. Brand fentanyl products only covered if documentation is submitted indicating past failure or intolerance to generic oral transmucosal fentanyl. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or pain specialist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FERRIPROX
<b>Drug Names</b>	FERRIPROX
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Must have transfusional iron overload due to thalassemia syndromes. Must have adequate trial of iron chelator such as deferoxamine or deferasirox. Must have an assessment of ANC prior to starting deferiprone. For reauth: must have documentation from prescriber indicating improvement in condition and showing that ANC is being monitored on a weekly basis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FETZIMA
<b>Drug Names</b>	FETZIMA, FETZIMA TITRATION PACK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Concomitant therapy with monoamine oxidase inhibitor, linezolid, or intravenous methylene blue.
<b>Required Medical Information</b>	Diagnosis. Must have adequate trial and failure of one generic serotonin norepinephrine reuptake inhibitor (such as venlafaxine ER) indicated for the treatment of major depressive disorder AND one generic selective serotonin reuptake inhibitor (such as citalopram or fluoxetine). If transitioning from a monoamine oxidase inhibitor to levomilnacipran, must have at least a 14-day washout period in between.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	FIRST GENERATION ANTIHISTAMINES - PENDING CMS REVIEW
<b>Drug Names</b>	CARBINOXAMINE MALEATE, CLEMASTINE FUMARATE, CYPROHEPTADINE HCL, HYDROXYZINE HCL, HYDROXYZINE PAMOATE, PROMETHAZINE HCL
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	

<b>Prior Authorization Group</b>	FYCOMPA
<b>Drug Names</b>	FYCOMPA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have had an inadequate response or intolerance to 2 other antiepileptic drugs (such as carbamazepine, oxcarbazepine, or phenytoin) and be using perampanel as adjunctive therapy to other antiepileptic drugs (which can include medication from trial above). Must have documentation indicating the member will be monitored for the psychiatric side effects of the perampanel. For reauth: must have documentation from prescriber indicating improvement in condition and monitoring for psychiatric side effects.
<b>Age Restrictions</b>	Age 12 years or older
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	GAMASTAN
<b>Drug Names</b>	GAMASTAN S/D
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	GARDASIL
<b>Drug Names</b>	GARDASIL 9
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	Between the ages of 9 and 26 years
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	3 doses per 365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	GATTEX
<b>Drug Names</b>	GATTEX
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Active intestinal obstruction or active malignancy.
<b>Required Medical Information</b>	Diagnosis of short bowel syndrome defined as less than 200cm of residual functional small intestine. Must provide date of bowel resection, baseline parenteral or intravenous nutrition (PN/IV) support schedule including frequency and volume, colonoscopy within 6 months before starting teduglutide (if appropriate), and baseline (within 6 months) lab monitoring of bilirubin, alkaline phosphatase, lipase, and amylase. Must be receiving parenteral or intravenous nutrition support at least 3 times per week. For reauth: must have documentation from prescriber indicating improvement in condition, that member has weaned off or decreased PN/IV requirements, that the member had a colonoscopy (if appropriate) after 1 year of teduglutide treatment and at least every 5 years after the 1st year, and that member is undergoing laboratory testing of bilirubin, alkaline phosphatase, lipase, and amylase every 6 months.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	GAUCHER DISEASE AGENTS
<b><i>Drug Names</i></b>	CEREZYME, ELELYSO, VPRIV
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis of Gaucher disease with any of the following: anemia (defined as hemoglobin less than 12g/dL in males or less than 11g/dL in females for members older than 12 years of age, hemoglobin less than 10.5g/dL for members between 2 to 12 years of age, hemoglobin less than 9.5g/dL for members between 6 months to 2 years of age, or hemoglobin less than 10.1g/dL for members less than 6 months of age), thrombocytopenia (defined as platelet count less than 100,000), hepatomegaly (defined as liver size greater than or equal to 1.25 times normal), splenomegaly (defined as spleen size greater than 0.2% of body weight), or bone disease (defined as having one of the following: avascular necrosis, erlenmeyer flask deformity, lytic disease, marrow infiltrations, osteopenia, osteosclerosis, pathological fracture, or radiological evidence of joint deterioration). For reauth: must have documentation from prescriber indicating improvement in condition.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	By or in consultation with a hematologist, a physician who specializes in the treatment of inherited metabolic disorders, or a center that specializes in the treatment of Gaucher disease.
<b><i>Coverage Duration</i></b>	365 days
<b><i>Other Criteria</i></b>	Not Applicable
<b><i>Prior Authorization Group</i></b>	GILOTRIF
<b><i>Drug Names</i></b>	GILOTRIF
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. For first line treatment of metastatic non-small cell lung cancer, must have chart documentation of lab result confirming epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	Oncologist or hematologist
<b><i>Coverage Duration</i></b>	365 days
<b><i>Other Criteria</i></b>	Not Applicable

<b>Prior Authorization Group</b>	GLEOSTINE
<b>Drug Names</b>	GLEOSTINE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	GRALISE
<b>Drug Names</b>	GRALISE, GRALISE STARTER
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Postherpetic Neuralgia. Must have adequate trial and failure of tricyclic antidepressant unless contraindicated. Must have adequate trial and failure of gabapentin defined as either failure due to insufficient efficacy at dose of at least 1800mg/day OR chart documented failure due to intolerance despite slow dose titration.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	GRASTEK
<b>Drug Names</b>	GRASTEK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	History of any severe systemic allergic reaction. History of eosinophilic esophagitis. Severe, unstable or uncontrolled asthma. On concomitant immunotherapy.
<b>Required Medical Information</b>	Diagnosis. Must have moderate to severe grass pollen-induced allergic rhinitis with or without conjunctivitis. Must have diagnosis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens (i.e. Sweet Vernal, Orchard, Perennial Rye, Kentucky Blue Grass) and chart documentation demonstrating seasonal symptoms to grass-pollen from the previous pollen season. Must have chart documentation demonstrating daily concomitant use of an inhaled nasal corticosteroid (i.e. fluticasone) and an oral antihistamine (i.e. levocetirizine) during the previous pollen season with inadequate responses or significant side effects/toxicities or have contraindication to these therapies. Must have plan for first dose to be administered in physician office due to potential for life-threatening allergic reactions, including anaphylaxis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 5 years through 65 years
<b>Prescriber Restrictions</b>	Allergist or immunologist
<b>Coverage Duration</b>	180 days
<b>Other Criteria</b>	Therapy must be initiated 12 weeks prior to the onset of grass pollen season. For sustained effectiveness for one grass pollen season after cessation of treatment, may be taken daily for 3 consecutive years (including intervals between grass pollen seasons).

<b>Prior Authorization Group</b>	GROWTH HORMONE - PENDING CMS REVIEW
<b>Drug Names</b>	GENOTROPIN, GENOTROPIN MINIQUICK, HUMATROPE, HUMATROPE COMBO PACK, NORDITROPIN FLEXPOR, NUTROPIN AQ NUSPIN 10, NUTROPIN AQ NUSPIN 20, NUTROPIN AQ NUSPIN 5, OMNITROPE, SAIZEN, SAIZEN CLICK.EASY, ZOMACTON
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	



<b>Prior Authorization Group</b>	HETLIOZ
<b>Drug Names</b>	HETLIOZ
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must submit chart documentation describing how diagnosis was confirmed (e.g. sleep-wake logs, melatonin secretion abnormalities, or progress notes, etc.). Patient must be totally blind with no perception of light. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By a neurologist or physician who specializes in sleep medicine
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	HORIZANT
<b>Drug Names</b>	HORIZANT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For RLS: must have adequate trial and failure of pramipexole or ropinirole (defined as insufficient efficacy of pramipexole 0.5mg per day or ropinirole 4mg per day or intolerance to these meds) AND must have adequate trial and failure of gabapentin (defined as insufficient efficacy of gabapentin 1800mg per day or intolerance to med despite slow dose titration or contraindication). For PHN: must have adequate trial and failure of gabapentin (defined as insufficient efficacy of gabapentin 1800mg per day or intolerance to med despite slow dose titration or contraindication) AND must have adequate trial of tricyclic antidepressant unless intolerant or contraindicated.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	HUMAN CHORIONIC GONADOTROPIN
<b>Drug Names</b>	CHORIONIC GONADOTROPIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Diagnoses not covered: ovulation induction, obesity.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Age 4 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	HUMIRA
<b>Drug Names</b>	HUMIRA, HUMIRA PEDIATRIC CROHNS D, HUMIRA PEN, HUMIRA PEN-CROHNS DISEASE, HUMIRA PEN-PSORIASIS STAR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. Use of TNF-blocking or other biologic agent in combination with adalimumab.
<b>Required Medical Information</b>	Negative TB skin test. For plaque psoriasis (PS): must have chronic mod to severe dx. For ankylosing spondylitis (AS): must have active dx. For all other dx: must have mod to severely active dx. For RA, JIA: adeq trial of methotrexate (MTX) with inadeq response (if sig. side effects/toxicity or contraindication (CI) to MTX must have adequate trial of hydroxychloroquine, leflunomide, or sulfasalazine for RA and of leflunomide or sulfasalazine for JIA). For psoriatic arthritis (peripheral disease): adeq trial of 1 NSAID at target anti-inflammatory dose and 1 conventional systemic tx (e.g. MTX, cyclosporine, leflunomide, sulfasalazine) with inadeq response or sig. side effects/toxicities unless CI. For psoriatic arthritis (axial, skin, nail, enthesitis, or dactylitis dominant): adeq trial of 2 NSAIDs at target anti-inflam dose with inadeq response or sig. side effects/toxicities unless CI. For AS: adeq trial of 2 NSAIDs at target anti-inflam dose with inadeq response or sig. side effects/toxicity or have a CI. For PS: min BSA of at least 5% (not req if on palms, soles, head/neck, genitalia), adeq trial of 1 topical treatment or phototherapy or photochemotherapy with inadeq response or sig. side effects/toxicity unless contraindicated, and adeq trial of 1 conventional systemic therapy (e.g. MTX, acitretin, cyclosporine) with inadeq response or sig. side effects/toxicity unless CI. For Crohns, UC: adeq trial of 1 conventional therapy incl corticosteroid, 5-ASA agent (UC only), or immunosuppressant with inadeq response or sig. side effects/toxicity unless CI. For hidradenitis suppurativa (HS): mod or severe dx (w/ 3 active abscesses, inflammatory nodules, or lesions). For uveitis: adeq trial of 1 immunosuppressant (e.g. MTX, mycophenolate, tacrolimus, cyclosporine) with inadeq response or sig. side effects/toxicity unless CI. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	JIA: age 2 years or older. Crohns: age 6 years or older. Other dx: age 18 years or older.
<b>Prescriber Restrictions</b>	RA, JIA, ankylosing spondylitis: rheumatologist. Psoriatic arthritis: rheumatologist, dermatologist. Plaque psoriasis, HS: dermatologist. Crohn's, UC: gastroenterologist. Uveitis: ophthalmologist, rheumatologist.
<b>Coverage Duration</b>	HS initial: 90 days. HS reauth: 365 days. All other dx: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	HYDROXYPROGESTERONE
<b>Drug Names</b>	HYDROXYPROGESTERONE CAPRO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Known or suspected carcinoma of the breast, other hormone-sensitive cancer, or history of such conditions. Undiagnosed abnormal vaginal bleeding. Liver dysfunction or disease. Missed abortion. History of hypersensitivity. Current or history of thrombotic or thromboembolic disorders. Use as diagnostic test for pregnancy.
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	IBRANCE
<b>Drug Names</b>	IBRANCE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	ICLUSIG
<b>Drug Names</b>	ICLUSIG
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist or Hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ILARIS
<b>Drug Names</b>	ILARIS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. Use of TNF-blocking or other biologic agent with canakinumab.
<b>Required Medical Information</b>	Negative TB skin test. For FMF, HIDS, MKD, TRAPS: see Other Criteria. Muckle-Wells (MWS): must have chart doc of diagnosis (dx) confirmed by genetic test (must have doc of lab result confirming mutation in NLRP3 gene) or clinical dx (must have 3 of following: autosomal dominant pattern of disease inheritance, severe fatigue, musculoskeletal symptoms, ocular symptoms, erythematous rash, history of intermittent episodes of fever for at least 24 hours, amyloidosis, hearing loss). Familial Cold Autoinflammatory Syndrome (FCAS): must have chart doc of dx confirmed by genetic test (must have doc of lab result confirming mutation in NLRP3 gene) or a clinical dx (must have 3 of following: recurrent intermittent episodes of fever and rash that primarily follow natural/experimental/both types of generalized cold exposures, autosomal dominant pattern of disease inheritance, age of onset less than 6 months of age, conjunctivitis associated with attacks, absence of deafness/periorbital edema/lymphadenopathy/serositis). SJIA: must have chart doc of dx (must have all of following: history of fever for at least 2 week duration, history of arthritis in 1 or more joints, history of one of following erythematous rash, generalized enlarged lymph nodes, hepatomegaly or splenomegaly, pericarditis/pleuritis/peritonitis), must have active disease (must have 1 of following: erythrocyte sedimentation rate or C-reactive protein level greater than twice upper limit of normal, active fever, active arthritis), must have adequate trial of methotrexate and anakinra with inadequate response or sig side effect/toxicities or contraindication if arthritis currently active OR must have adequate trial of corticosteroid and anakinra with inadequate responses or sig side effects/toxicity or contraindication if arthritis currently not active. Reauth: must have doc from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	MWS, FCAS, FMF, HIDS, MKD, TRAPS: rheumatologist, dermatologist, immunologist, or genetic specialist. SJIA: pediatric rheumatologist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 90 days (FMF, HIDS, MKD, TRAPS), 365 days (MWS, FCAS, SJIA).
<b>Other Criteria</b>	For Familial Mediterranean Fever (FMF): must have chart doc of dx confirmed by genetic test (must have doc of lab result confirming mutation in MEFV gene) or a clinical dx (must have 3 of following: history of intermittent episodes of fever and pain for 1-3 days duration, autosomal recessive pattern of disease inheritance, presence of peritonitis, presence of arthritis, presence of pleuritis, or presence of erysipelas-like erythema) AND must have adequate trial of colchicine with inadequate response or sig side effects/toxicity unless contraindicated. For Hyperimmunoglobulin D Syndrome (HIDS) and Mevalonate Kinase Deficiency (MKD): must have chart doc of dx confirmed by genetic test (must have doc of lab result confirming mutation in MVK gene) or a clinical dx (must have 3 of following: history of intermittent episodes of fever and inflammation for at least 3 days duration, autosomal recessive pattern of disease

inheritance, presence of painful lymph nodes, presence of joint pain, presence of headache, presence of hepatosplenomegaly, presence of skin rash, or presence of abdominal pain, vomiting, diarrhea). For Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): must have chart doc of dx confirmed by genetic test (must have doc of lab result confirming mutation in TNFRSF1A gene) or a clinical dx (must have 3 of following: history of intermittent episodes of fever for at least 1 week duration, autosomal dominant pattern of disease inheritance, presence of painful lymph nodes, presence of headache, presence of skin rash, presence of muscle cramps, presence of abdominal pain, presence of pleuritis, presence of pericarditis, presence of conjunctivitis or periorbital edema).

<b>Prior Authorization Group</b>	IMATINIB
<b>Drug Names</b>	IMATINIB MESYLATE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	IMBRUVICA
<b>Drug Names</b>	IMBRUVICA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	IMMUNE GLOBULINS
<b>Drug Names</b>	BIVIGAM, CARIMUNE NANOFILTERED, FLEBOGAMMA DIF, GAMMAGARD LIQUID, GAMMAGARD S/D IGA LESS TH, GAMMAKED, GAMMAPLEX, GAMUNEX-C, HIZENTRA, OCTAGAM, PRIVIGEN
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Primary immunodeficiency: IgG less than 500mg/dL (clinical rationale for use required if IgG is 500mg/dL or greater) and history of at least 1 bacterial infection directly attributable to deficiency for initial auth and recent IgG level for reauth. Children w/ ITP: platelet count less than: 20,000 and significant mucous membrane bleeding, 10,000 and minor purpura, or 20,000 and inaccessibility or noncompliance is concern, OR need for any surgery, dental extraction, or other procedure likely to cause blood loss. Adults w/ ITP: plt count less than 30,000 and previous documented inadequate response or intolerance to corticosteroids OR need for surgery likely to cause blood loss (platelet count less than or equal to: 10,000 for dentistry, 30,000 for tooth extraction or regional dental block, 50,000 for minor surgery, 80,000 for major surgery). For pregnant women w/ ITP: plt count less than 100,000, history of splenectomy, or previous delivery of infant(s) w/ autoimmune thrombocytopenia. B-Cell CLL: IgG less than 500mg/dL and previous history of serious bacterial infection requiring antibiotics. CIDP: doc of electrodiagnostic testing confirming dx. Multifocal Motor Neuropathy: must have conduction block and progressive symptomatic disease diagnosed on basis of electrophysiologic findings to r/o other possible conditions. For reauth (all dx): must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Primary immunodeficiency: by or in consultation w/ immunologist, hematologist. ITP: hematologist, oncologist. B-cell CLL: hematologist, oncologist, ID specialist. CIDP, Multifocal Motor Neuropathy: neurologist.
<b>Coverage Duration</b>	ITP: 30 days. CIDP, multifocal motor neuropathy: 90 days. Other dx: 365 days.
<b>Other Criteria</b>	BvsD determination will be made prior to clinical criteria being applied.

<b>Prior Authorization Group</b>	INCRELEX - PENDING CMS REVIEW
<b>Drug Names</b>	INCRELEX
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	

**Prior Authorization Group** INLYTA  
**Drug Names** INLYTA  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** Oncologist or Hematologist  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

**Prior Authorization Group** IRESSA  
**Drug Names** IRESSA  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis. Must have chart documentation of lab result confirming epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** Oncologist or hematologist  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

**Prior Authorization Group** ITRACONAZOLE - PENDING CMS REVIEW  
**Drug Names** ITRACONAZOLE  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

<b>Prior Authorization Group</b>	JAKAFI
<b>Drug Names</b>	JAKAFI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection
<b>Required Medical Information</b>	Diagnosis of intermediate or high-risk myelofibrosis (includes primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis). Must have a baseline platelet count of at least 50,000 cells/mm <sup>3</sup> prior to initiation of ruxolitinib. For diagnosis of polycythemia vera: must currently require phlebotomy and must have adequate trial of hydroxyurea with an inadequate response or significant side effect/toxicity unless contraindicated.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	JUXTAPID
<b>Drug Names</b>	JUXTAPID
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Members who are pregnant, who have moderate or severe hepatic impairment (Child-Pugh category B or C) or active liver disease, or who are on concomitant moderate or strong CYP3A4 inhibitors.
<b>Required Medical Information</b>	Diagnosis of homozygous familial hypercholesterolemia confirmed by genetic testing with functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality or have clinical diagnosis defined as one of the following (1) untreated LDL greater than 500mg/dL AND untreated total cholesterol (TC) greater than 500mg/dL and triglycerides (TG) less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (2) skin fibroblast LDL receptor activity less than 20% of normal AND untreated TC greater than 500mg/dL and TG less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (3) presence of cutaneous and tendon xanthomas and corneal arcus in first decade of life AND untreated TC greater than 500mg/dL and TG less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (4) untreated LDL greater than 500mg/dL AND skin fibroblast LDL receptor activity less than 20% of normal, (5) untreated LDL greater than 500mg/dL AND presence of cutaneous and tendon xanthomas and corneal arcus in first decade of life. Must have chart documentation of clinical work-up to rule out other diagnoses. For initial auth: baseline negative pregnancy test with date of test and be on effective contraception for females of reproductive potential, and baseline laboratory monitoring of LDL, total cholesterol, triglycerides, transaminases, alkaline phosphatase, and bilirubin with date of test. Must be on statin (e.g. atorvastatin, simvastatin) unless intolerant or contraindicated and another LDL-lowering medication from a different class (e.g. ezetimibe, colestipol) prior to starting lomitapide. For reauth: documentation from prescriber indicating improvement in condition, documentation of follow-up LDL levels showing reduction in LDL level since starting treatment, and documentation of monitoring of transaminase, alkaline phosphatase, and bilirubin levels.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Lipidologist, cardiologist, endocrinologist, or geneticist
<b>Coverage Duration</b>	Initial: 120 days. Reauth: 365 days.
<b>Other Criteria</b>	If clinical documentation confirms the member meets the prior authorization criteria, lomitapide will be approved after consultation with a Medical Director.

**Prior Authorization Group** KALYDECO - PENDING CMS REVIEW  
**Drug Names** KALYDECO  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** KANUMA  
**Drug Names** KANUMA  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** Allergy or sensitivity to eggs or egg products.  
**Required Medical Information** Diagnosis. Confirmation of genetic defect in the LIPA gene. For Lysosomal Acid Lypase (LAL) deficiency (Wolman disease): Documentation of growth failure not contributed to other causes and evidence of rapidly progressive disease confirmed via CT scan, MRI, or biopsy (such as hepatosplenomegaly, ascites, calcification of adrenal gland tissue, liver fibrosis confirmed through biopsy). For Cholesteryl Ester Storage Disease (CESD): documentation of the following- LDL-C greater than or equal to 130 mg/dL in pediatrics or greater than or equal to 160 mg/dl in adults, malabsorption and growth failure not contributed to other causes, calcification of adrenal gland tissue confirmed via CT scan or MRI, anemia (males greater than 12 years- Hgb less than 12 g/dl, females greater than 12 years- Hgb less than 11 g/dL, children 2 to 12 years- Hgb less than 10.5 g/dl, children 6 months to 2years- Hgb less than 9.5 g/dL), hepatomegaly confirmed via CT scan or MRI (liver size greater than or equal to 1.25 times normal), and splenomegaly (splenic mass greater than normal). For reauth: must have chart documentation that the condition has improved while on therapy.  
**Age Restrictions** Rapidly progressive lysosomal acid lypase (LAL) deficiency (Wolman disease): Age 1 month or older  
**Prescriber Restrictions** By or in consultation with a gastroenterologist, geneticist, lipidologist, or metabolic disorders specialist  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

<b>Prior Authorization Group</b>	KEVEYIS
<b>Drug Names</b>	KEVEYIS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Concomitant use with high dose aspirin. Severe pulmonary disease, limiting compensation to metabolic acidosis that may be caused by dichlorphenamide. Hepatic encephalopathy.
<b>Required Medical Information</b>	For primary hypokalemic periodic paralysis: must have documentation confirming diagnosis, defined as one of the following scenarios: two or more attacks of muscle weakness with documented serum K less than 3.5mEq/L, or one attack of muscle weakness in the member with documented serum potassium less 3.5mEq/L and one attack of weakness in a relative with a hx of the condition, or three of the following clinical/laboratory features: onset of symptoms in the first or second decade of life, duration of attack (muscle weakness involving one or more limbs) longer than two hours, presence of triggers (previous carbohydrate rich meal, symptom onset during rest after exercise or during stressful situations) for attacks, improvement in symptoms with potassium intake, family hx of the condition or genetically confirmed skeletal calcium or sodium channel mutation, positive long exercise test. For hyperkalemic periodic paralysis: must have documentation confirming diagnosis based on genetics or clinical presentation (see other coverage criteria).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Initial 90 days. Reauth: 365 days.
<b>Other Criteria</b>	For primary hypokalemic periodic paralysis: must have documentation excluding other causes of hypokalemia (renal, adrenal, thyroid dysfunction, renal tubular acidosis, diuretic and laxative abuse) and must currently be using a potassium supplement. For hyperkalemic periodic paralysis confirmed based on genetics testing: must have both of the following: family hx of the condition or genetically confirmed skeletal sodium channel mutation associated with hyperkalemic periodic paralysis and a hx of at least two attacks of flaccid limb weakness (which may also include weakness of the muscles of the eyes, throat, and trunk) or 1 attack with a family hx of attacks of hyperkalemic periodic paralysis. For hyperkalemic periodic paralysis confirmed based on clinical presentation must have all of the following: a hx of at least two attacks of flaccid limb weakness (which may also include weakness of the muscles of the eyes, throat, and trunk) or 1 attack with a family hx of attacks of hyperkalemic periodic paralysis, serum potassium greater than 5mEq/L or an increase of serum potassium concentration of at least 1.5 mEq/L during an attack of weakness and/or onset/worsening of an attack as a result of oral potassium intake, and presence of myotonia or any 3 of the following clinical features: typical attack duration less than 2 hours, onset before 30 years, positive long exercise test (greater than 40% decrement in CMAP), or typical external triggers (rest after exercise, potassium load, fasting). For hyperkalemic periodic paralysis: must have documentation of normal serum potassium concentration and muscle strength between attacks and electroencephalogram (ECG) recording for the exclusion of long QTc interval and ventricular arrhythmias. For hyperkalemic periodic

paralysis: must not have secondary hyperkalemic periodic paralysis due to ingestion of potassium or of a potassium sparing diuretic or paramyotonia (i.e. muscle stiffness that is worsening after exercise or cold-induced). For hyperkalemic periodic paralysis must have documentation of exclusion of other hereditary forms of hyperkalemia (i.e., Andersen-Tawil syndrome) and acquired forms of hyperkalemia (drug abuse, renal and adrenal dysfunction). For reauth: must have documentation from prescriber indicating improvement in condition.

<b>Prior Authorization Group</b>	KISQALI
<b>Drug Names</b>	KISQALI, KISQALI FEMARA 200 DOSE, KISQALI FEMARA 400 DOSE, KISQALI FEMARA 600 DOSE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	KORLYM
<b><i>Drug Names</i></b>	KORLYM
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	Pregnant. History of unexplained vaginal bleeding, endometrial hyperplasia with atypia, or endometrial carcinoma. Concomitant therapy with simvastatin, lovastatin, or CYP3A4 substrates with narrow therapeutic range (i.e. cyclosporine, tacrolimus). Concurrent long-term corticosteroid treatment.
<b><i>Required Medical Information</i></b>	Diagnosis. Must have failed surgery or not be a candidate for surgery (trans-sphenoidal surgery for pituitary dependent Cushing's or surgical removal of an adrenocortical tumor or a source of ectopic ACTH in malignant Cushing's). Female members of reproductive potential: must have baseline (within previous month, must include date of test) negative pregnancy test prior to starting mifepristone and must be using non-hormonal medically acceptable method of contraception (unless surgically sterilized) during treatment and for 1 month after mifepristone therapy. Must have baseline hemoglobin A1C level. Must have chart documentation of an adequate trial and failure of conventional anti-hyperglycemic medication. For reauth: must have documentation from prescriber indicating improvement in condition, must have documentation of recent (within previous month) negative pregnancy test including date of test if female of reproductive potential, and must have documentation of improvement in hyperglycemia control as evidenced by a reduction in blood glucose levels, HbA1c, or anti-hyperglycemic medication doses or number of medications.
<b><i>Age Restrictions</i></b>	Age 18 years or older
<b><i>Prescriber Restrictions</i></b>	By or in consultation with an endocrinologist
<b><i>Coverage Duration</i></b>	Initial: 90 days. Reauth: 365 days.
<b><i>Other Criteria</i></b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	KUVAN
<b><i>Drug Names</i></b>	KUVAN
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. Baseline serum phenylalanine level. For reauth: must have documentation from prescriber indicating response to therapy, follow-up serum phenylalanine level.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	No Prescriber Restrictions
<b><i>Coverage Duration</i></b>	Initial: 60 days. Reauth: 365 days.
<b><i>Other Criteria</i></b>	Continuation/Discontinuation criteria: lab reassessment will be conducted after an initial one month trial to determine if authorization may be extended. Patients on the 10mg/kg/day dose whose blood phenylalanine levels have not decreased from baseline after 1 month of treatment should increase to 20mg/kg/day. These patients will be approved for another one month trial at the higher dose. Patients on the 20mg/kg/day dose whose blood phenylalanine levels have not decreased from baseline after 1 month are considered non-responders, and treatment with Kuvan should be discontinued in these patients.

<b>Prior Authorization Group</b>	KYNAMRO
<b>Drug Names</b>	KYNAMRO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Severe hepatic impairment or active liver disease
<b>Required Medical Information</b>	Diagnosis of homozygous familial hypercholesterolemia confirmed by genetic testing with functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality or have clinical diagnosis defined as one of the following (1) untreated LDL greater than 500mg/dL AND untreated total cholesterol (TC) greater than 500mg/dL and triglycerides (TG) less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (2) skin fibroblast LDL receptor activity less than 20% of normal AND untreated TC greater than 500mg/dL and TG less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (3) presence of cutaneous and tendon xanthomas and corneal arcus in first decade of life AND untreated TC greater than 500mg/dL and TG less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (4) untreated LDL greater than 500mg/dL AND skin fibroblast LDL receptor activity less than 20% of normal, (5) untreated LDL greater than 500mg/dL AND presence of cutaneous and tendon xanthomas and corneal arcus in first decade of life. Must have chart documentation of clinical work-up to rule out other diagnoses. For initial auth: baseline laboratory monitoring of LDL, total cholesterol, triglycerides, transaminases, alkaline phosphatase, and bilirubin with date of test. Must be on statin (e.g. atorvastatin, simvastatin) unless intolerant or contraindicated and another LDL-lowering medication from a different class (e.g. ezetimibe, colestipol) prior to starting mipomersen. For reauth: documentation from prescriber indicating improvement in condition, documentation of follow-up LDL levels showing reduction in LDL level since starting treatment, and documentation of monitoring of transaminase, alkaline phosphatase, and bilirubin levels.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Lipidologist, cardiologist, or endocrinologist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	If clinical documentation confirms the member meets the prior authorization criteria, mipomersen will be approved after consultation with a Medical Director.

<b>Prior Authorization Group</b>	LENVIMA
<b>Drug Names</b>	LENVIMA 10 MG DAILY DOSE, LENVIMA 14 MG DAILY DOSE, LENVIMA 18 MG DAILY DOSE, LENVIMA 20 MG DAILY DOSE, LENVIMA 24 MG DAILY DOSE, LENVIMA 8 MG DAILY DOSE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	LETAIRIS
<b>Drug Names</b>	LETAIRIS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have baseline negative pregnancy prior to initiation of therapy if a female of child-bearing potential. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	LEUKINE
<b>Drug Names</b>	LEUKINE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For AML: must be receiving induction chemotherapy. For bone marrow transplant, must have one of the following: must require administration after autologous (not allogeneic) bone marrow transplant for NHL/ALL/Hodgkin's disease, must require mobilization of progenitor cells into peripheral blood (often in conjunction with chemotherapy) for collection by leukapheresis, must have undergone allogeneic bone marrow transplant from HLA-matched related donor, OR must have undergone allogeneic or autologous bone marrow transplantation where engraftment is delayed or has failed. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	AML: age 55 years or older. BMT: age 18 years or older.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	90 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	LEUPROLIDE AND DERIVATIVES
<b>Drug Names</b>	ELIGARD, FIRMAGON, LEUPROLIDE ACETATE, LUPANETA PACK, LUPRON DEPOT (1-MONTH), LUPRON DEPOT (3-MONTH), LUPRON DEPOT (4-MONTH), LUPRON DEPOT (6-MONTH), LUPRON DEPOT-PED (1-MONTH, SYNAREL, TRELSTAR MIXJECT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For endometriosis: must have diagnosis confirmed by laparoscopy OR chart documentation of clinical work-up and clinical rationale for diagnosis, and must have trial and failure of oral contraceptives and/or progestins for mild disease. For fibroids: must be used preoperatively to maximize hemoglobin in patients with documented anemia (Hgb less than 11g/dL), or preoperatively to decrease size of fibroid uterus so less invasive route of hysterectomy can be attempted, or must provide clinical rationale if using outside context of preoperative adjuvant therapy in the surgical management of fibroids. For central precocious puberty: must have onset of secondary sexual characteristics earlier than age 8 years in females and 9 years in males. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Central Precocious Puberty: only be approved up to age 11 years in females and age 12 years in males
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Cancer, CPP: 365 dys. Endometriosis: 180 dys. Fibroid: 90 dys.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	LIDOCAINE PATCH
<b>Drug Names</b>	LIDOCAINE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	LONSURF
<b>Drug Names</b>	LONSURF
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. ECOG Performance Status.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	LYNPARZA
<b>Drug Names</b>	LYNPARZA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming BRCA mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	LYRICA
<b>Drug Names</b>	LYRICA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For fibromyalgia: must have chart documentation of diagnosis with history of widespread pain involving extremities for 3 months and localized area of tenderness, must have trial and failure of or intolerance to gabapentin at a dose of at least 1200mg/day AND either a tricyclic antidepressant or muscle relaxant unless contraindicated. For PHN: must have trial and failure of gabapentin or a tricyclic antidepressant. For DPN: must have documented pharmacy claim history or prior therapy with a diabetic medication OR a medical/lab claim or physician chart note of diabetes diagnosis, must have trial and failure of gabapentin.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MAKENA
<b>Drug Names</b>	MAKENA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Current or history of thrombosis or thromboembolic disorders. Known or suspected breast cancer or other hormone-sensitive cancer or history of these disorders. Undiagnosed abnormal vaginal bleeding unrelated to pregnancy. Cholestatic jaundice of pregnancy. Liver tumors (benign or malignant) or active liver disease. Uncontrolled hypertension
<b>Required Medical Information</b>	Diagnosis of singleton pregnancy. History of singleton spontaneous preterm birth. Must be starting or have started treatment between 16 weeks, 0 days and 20 weeks, 6 days of gestation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	22 weeks
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MEGESTROL
<b>Drug Names</b>	MEGESTROL ACETATE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist, hematologist, or HIV specialist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MEKINIST
<b>Drug Names</b>	MEKINIST
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Treatment with prior BRAF-inhibitor therapy if using trametinib as monotherapy
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming BRAFV600E or BRAFV600K mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MEMANTINE
<b>Drug Names</b>	MEMANTINE HCL, MEMANTINE HCL TITRATION P, MEMANTINE HYDROCHLORIDE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of moderate to severe dementia of Alzheimer's type.
<b>Age Restrictions</b>	Must be age 18 or older. Age 18 to 40 years: criteria apply. Age greater than 40 years: criteria do not apply.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	METHAMPHETAMINE
<b>Drug Names</b>	METHAMPHETAMINE HCL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Age 6 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	METHOXSALEN
<b>Drug Names</b>	METHOXSALEN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For psoriasis: must have severe, recalcitrant, disabling psoriasis confirmed by biopsy, must use in conjunction with UVA light therapy, and must have an adequate trial of 2 topical treatments (e.g. calcipotriene, fluocinonide, bethamethasone, hydrocortisone, clobetasol propionate) with an inadequate response or significant side effects /toxicity or have a contraindication. For cutaneous T-cell lymphoma: must use with UVAR system. For vitiligo: must use in conjunction with UVA light therapy and must have an adequate trial of calcipotriene with an inadequate response or significant side effect/toxicity or have a contraindication. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Psoriasis, vitiligo: dermatologist. Cutaneous T-cell lymphoma: dermatologist or oncologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MODAFINIL
<b>Drug Names</b>	MODAFINIL
<b>Covered Uses</b>	All medically-accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Chart documentation of sleep study confirming diagnosis for narcolepsy and OSA. For narcolepsy: must have adequate trial and failure of CNS stimulant (e.g. amphetamine salts, dextroamphetamine, methylphenidate). For shift-work sleep disorder (SWSD): must meet International Classification of Sleep Disorders criteria for SWSD (either primary complaint of excessive sleepiness or insomnia temporarily associated w/ work period that occurs during habitual sleep phase OR polysomnography and Multiple Sleep Latency Test demonstrate loss of normal sleep-wake pattern, no other medical or mental disorders account for symptoms, and symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness such as time zone change syndrome) and must provide chart documentation of shift work schedule showing 5 or more night shifts per month (defined as at least 4 hours of shift occurring between 10pm and 8am). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	SWSD: 180 days. Narcolepsy, OSA: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MOZOBIL
<b>Drug Names</b>	MOZOBIL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Non-Hodgkin's Lymphoma or multiple myeloma and require hematopoietic stem cell mobilization for collection and subsequent autologous transplantation. Must be used in combination with granulocyte colony stimulating factor (G-CFS) and be initiated after receipt of G-CFS daily for 4 days. Must have documentation that plerixafor will be administered 11 hours prior to initiation of apheresis for up to 4 consecutive days. For reauth: must meet initial auth criteria.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Bone marrow transplant specialist, hematologist, or oncologist
<b>Coverage Duration</b>	4 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MULTIPLE SCLEROSIS - PENDING CMS REVIEW
<b>Drug Names</b>	AUBAGIO, BETASERON, COPAXONE, GILENYA, GLATOPA, TYSABRI
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	

<b>Prior Authorization Group</b>	MYALEPT
<b>Drug Names</b>	MYALEPT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	HIV-related lipodystrophy
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of a clinical work-up to rule out other diagnoses and clinical rationale for the diagnosis and exclusion of other diagnoses. Must have severe insulin resistance resulting in diabetes mellitus (a hemoglobin A1c of at least 7% or fasting plasma glucose of at least 126mg/dL) with chart documentation showing an adequate trial of diabetic pharmacotherapy (such as with an insulin product) that did not allow the member to achieve adequate glucose control with optimized medication regimen AND/OR must have severe hypertriglyceridemia (triglyceride level of at least 500mg/dL) with chart documentation of an adequate trial of lipid-lowering pharmacotherapy (such as a fibrate, omega-3 fatty acid, or statin) that did not allow the member to achieve adequate triglyceride control with optimized medication regimen. For reauth: must have documentation from prescriber indicating benefit with metreleptin treatment (as evidenced by decrease in hemoglobin A1c, fasting plasma glucose, and/or triglyceride levels from baseline).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MYOZYME AND LUMIZYME
<b>Drug Names</b>	LUMIZYME
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Confirmed diagnosis of alpha glucosidase deficiency (Pompe disease). For reauth: must have documentation from prescribing indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	MYTESI
<b>Drug Names</b>	MYTESI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must be actively utilizing antiretroviral agents to treat HIV/AIDS. Must have documentation of persistent loose stools despite regular use of at least one anti-diarrheal medication (e.g. loperamide, diphenoxylate/atropine). For reauth: must have documentation from prescriber indicating improvement in condition, decrease in number of watery bowel movements, and continuous use of antiretroviral agents for HIV/AIDS.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	HIV or infectious disease specialist
<b>Coverage Duration</b>	Initial: 30 days. Reauth: 180 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	NAGLAZYME
<b>Drug Names</b>	NAGLAZYME
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 3 months or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable



**Prior Authorization Group** NATPARA - PENDING CMS REVIEW  
**Drug Names** NATPARA  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** NEULASTA  
**Drug Names** NEULASTA  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis. Must be receiving chemo regimen with dosing frequency of once every 2 wks or greater. For primary prophylaxis of febrile neutropenia (FN): must be receiving either myelosuppressive chemo regimen with greater than 20% risk of FN (per ASCO or NCCN guidelines) or non-myelosuppressive chemo regimen (less than or equal to 20% risk of FN) and considered to be at high risk for chemo-induced FN or infection with at least one risk factor (age 65 years or older, poor performance status, previous episode of FN, extensive prior treatment including large radiation ports, previous chemotherapy or radiation therapy, pre-existing neutropenia, cytopenia due to bone marrow involvement by tumor, poor nutritional status, presence of open wounds or active infection, recent surgery, advanced cancer, liver dysfunction such as elevated bilirubin, or other serious comorbidities). For secondary prophylaxis of FN: must have experienced a neutropenic complication from prior chemo cycle for which primary prophylaxis was not received and in which reduced dose may compromise disease-free or overall survival or treatment outcome. For reauth: must have documentation from prescriber indicating improvement in condition.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** No Prescriber Restrictions  
**Coverage Duration** 90 days  
**Other Criteria** Not Applicable

<b>Prior Authorization Group</b>	NEUPOGEN
<b>Drug Names</b>	GRANIX, NEUPOGEN, ZARXIO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D and diagnoses of agranulocytosis and myelodysplastic syndrome
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Primary prophylaxis of FN: must be receiving myelosuppressive chemo with greater than 20% FN risk OR non-myelosuppressive chemo (less than or equal to 20% FN risk) and considered high risk for chemo-induced FN or infection with at least 1 risk factor (see other criteria) OR dose-dense chemo for tx of node + breast ca, small-cell lung ca, or diffuse aggressive Non-Hodgkin's Lymphoma. Secondary prophylaxis of FN: must have experienced neutropenic complication from prior chemo cycle for which primary prophylaxis not received and in which reduced dose may compromise disease-free or overall survival or tx outcome. Tx of febrile pts w/ neutropenia: must have fever and neutropenia and be at high risk for infection-related complications or have prognostic factors predictive of poor clinical outcomes, have at least one risk factor (see other criteria), AND not have received prophylactic pegfilgrastim during current chemo cycle. Bone marrow txfr: must be used after autologous peripheral blood progenitor cell transplant OR mobilization of progenitor cells into peripheral blood (often in conjunction with chemo) for collection by leukapheresis. AML: must be receiving induction or consolidation tx. ALL: must be using after completion of initial 1st few days of chemo of initial induction or 1st post-remission course. Myelodysplastic syndrome: must have severe neutropenia and recurrent infection. Pts receiving radiation: must be receiving radiation tx w/o concomitant chemo w/ expected prolonged delays due to neutropenia. Older lymphoma pts: must have dx of acute aggressive lymphoma tx w/ curative chemo (CHOP or more aggressive regimen). Congenital, cyclic, or idiopathic neutropenia: must have symptomatic neutropenia. Drug-induced agranulocytosis: must have severe neutropenia w/ fever or serious infection as result of myelosuppressive regimen. For reauth: must have doc from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Neupogen, Zarxio: no age restrictions. Granix: age 18 years or older.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	90 days
<b>Other Criteria</b>	% risk of FN based on ASCO or NCCN guidelines. Risk factors for primary prophylaxis of FN: age 65 years or older, poor performance status, previous episode of FN, extensive prior treatment including large radiation ports, previous chemotherapy or radiation therapy, pre-existing neutropenia, cytopenia due to bone marrow involvement by tumor, poor nutritional status, presence of open wounds or active infection, recent surgery, advanced cancer, liver dysfunction such as elevated bilirubin, or other serious comorbidities. Risk factors for tx of febrile pts w/ neutropenia: sepsis syndrome, expected prolonged neutropenia for greater than 10 days, severe neutropenia with ANC less than 100/microliter, age 65 years or older, uncontrolled primary disease, pneumonia, hypotension and multi-organ dysfunction (sepsis syndrome), invasive fungal infection, other clinically documented infections, hospitalization at time of fever,

prior episode of febrile neutropenia. For treatment of febrile patients w/ neutropenia: must not have received pegfilgrastim during current chemotx cycle.

<b>Prior Authorization Group</b>	NEUPRO
<b>Drug Names</b>	NEUPRO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For Parkinson's disease: must have adequate trial and failure of pramipexole or ropinirole. For Restless Legs Syndrome: must have moderate to severe dx, must have adequate trial and failure of pramipexole or ropinirole (defined as insufficient efficacy of pramipexole 0.5mg per day or ropinirole 4mg per day, intolerance to a lower dose of one of these medications, or contraindication) AND must have adequate trial and failure of gabapentin.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	NEXAVAR
<b>Drug Names</b>	NEXAVAR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	NINLARO
<b>Drug Names</b>	NINLARO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	NORTHERA
<b><i>Drug Names</i></b>	NORTHERA
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis of symptomatic neurogenic hypotension caused by 1 of following: primary autonomic failure (e.g. Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy. Must have chart doc showing how diagnosis made, incl BP readings showing systolic blood pressure decrease of at least 20mmHg or diastolic blood pressure decrease of at least 10mmHg within 3 minutes of standing. Must have doc that member is symptomatic as result of low BP readings, including doc to support that member is experiencing at least 1 of the following symptoms: dizziness, lightheadedness, feeling faint, feeling like might black out. Must have chart doc indicating d/c or dose decrease of drugs which can cause orthostatic hypotension such as anti-hypertensives, nitrates, alpha-1 blockers (i.e. terazosin, prazosin), antiparkinsonian agents (i.e. levodopa, bromocriptine, ropinirole, pramipexole), diuretics, monoamine oxidase inhibitors, narcotics/tranquilizers/sedatives, drugs for erectile dysfunction, tricyclic antidepressants. Must have an adequate trial of midodrine. For reauth: must have doc from prescriber indicating improvement in condition as evidenced by improvement in the symptoms member was experiencing (i.e. dizziness, lightheadedness, feeling faint, or feeling like might black out) and showing member is being monitored for adverse effects (i.e. supine hypertension) and additional drugs have not been added to the drug regimen that would cause supine hypertension.
<b><i>Age Restrictions</i></b>	Age 18 years or older
<b><i>Prescriber Restrictions</i></b>	Cardiologist or neurologist
<b><i>Coverage Duration</i></b>	Initial: 1 month. Reauth: 6 months.
<b><i>Other Criteria</i></b>	Not Applicable

<b>Prior Authorization Group</b>	NOXAFIL
<b>Drug Names</b>	NOXAFIL
<b>Covered Uses</b>	All medically-accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Members on the following medications: terfenadine, astemizole, cisapride, pimozone, halofantrine, quinidine, sirolimus.
<b>Required Medical Information</b>	Diagnosis. For prophylaxis of Aspergillus and Candida infections (tablet, injection, or suspension): must be severely immunocompromised. For treatment of oropharyngeal candidiasis (suspension): must have trial and failure of fluconazole or itraconazole for at least 2 weeks. For reauth: must have documentation from prescriber indicating clinical rationale for retreatment.
<b>Age Restrictions</b>	Injection: age 18 years or older, Tablet or suspension: age 13 years or older.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Prophy of Aspergillus/Candida: 120 dys. Oropharyngeal Candidiasis: 30 dys.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	NUCALA
<b>Drug Names</b>	NUCALA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have severe persistent asthma. Must have blood eosinophil count of greater than 150 cells/uL within the past six weeks (while on corticosteroid) or greater than or equal to 300 cells/uL within past year, including date test performed. Must have adequate trial of combination therapy with an ICS/LABA (inhaled corticosteroid/long-acting beta-agonist, such as Advair, Breo Ellipta, or Dulera) AND either a LAMA (long-acting muscarinic antagonist, such as Spiriva or Incruse Ellipta) or a leukotriene receptor antagonist (such as montelukast) with inadequate response or significant side effects/toxicities or have a contraindication to these therapies. Must have asthma symptoms that continue to be uncontrolled on optimized medication therapy regimen (uncontrolled defined as hospitalization for asthma within past year, requirement for oral or parenteral corticosteroids to control exacerbations of asthma on 2 occurrences in the past year, or need for daily corticosteroid with inability to taper off). For reauth: must have documentation from prescriber indicating improvement in condition (such as reduced exacerbations, hospitalizations, emergency department visits, or requirement for oral corticosteroid therapy).
<b>Age Restrictions</b>	Age 12 years or older
<b>Prescriber Restrictions</b>	By or in consultation with an allergist, an immunologist, or a pulmonologist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	NUEDEXTA
<b>Drug Names</b>	NUEDEXTA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Members on quinidine, quinine, mefloquine, MAOIs in the last 14 days, drugs that prolong the QT interval and are metabolized by CYP2D6. History of hypersensitivity to quinidine, quinine, mefloquine, or dextromethorphan. Diagnosis of prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, heart failure, complete AV (atrioventricular) block without an implanted pacemaker, or high risk of complete AV block
<b>Required Medical Information</b>	Diagnosis of pseudobulbar affect (PBA) supported by chart documentation of the following: involuntary outbursts of laughing and/or crying that are incongruous or disproportionate to the patient's emotional state AND documentation of a clinical work-up, including clinical rationale for the PBA diagnosis and exclusion of other possible conditions that could result in emotional lability (e.g. depression, bipolar disorder, schizophrenia, epilepsy). Must have underlying neurological disorder such as amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's and related diseases, Stroke, Traumatic Brain Injury, or Parkinsonian Syndrome. For reauth: must have documentation from prescriber indicating decrease in number of laughing and/or crying episodes as a result of therapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with neurologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	NULOJIX
<b>Drug Names</b>	NULOJIX
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection, including, but not limited to: Progressive multifocal leukoencephalopathy, Cytomegalovirus, Polyoma virus-associated neuropathy. History of or currently active malignancy.
<b>Required Medical Information</b>	Diagnosis. Negative tuberculosis skin test. EBV seropositive as demonstrated by EBV serology. Must be undergoing or have undergone renal transplant. Must be at increased risk of renal failure before transplant OR must have tried and failed or have intolerance to tacrolimus or cyclosporine unless contraindicated. Must be used in conjunction with basiliximab induction if given at time of transplant, mycophenolate mofetil, and corticosteroids.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Physician who specializes in immunosuppression or renal transplantation.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	B vs. D determination will be made prior to clinical criteria being applied.

<b>Prior Authorization Group</b>	NUPLAZID
<b>Drug Names</b>	NUPLAZID
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must provide chart documentation of clinical work-up to rule out other diagnoses. Clinical rationale for diagnosis and exclusion of other diagnoses must be provided. Must have tried to discontinue or reduce the dose of any medication(s) that may cause or contribute to hallucinations and delusions (i.e. dopamine agonists, amantadine, monoamine oxidase B inhibitors, anticholinergics) or provide clinical rationale indicating why dose reduction or discontinuation of applicable medications would not be appropriate.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a psychiatrist or neurologist that specializes in the treatment of movement disorders
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	OCALIVA
<b>Drug Names</b>	OCALIVA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Complete biliary obstruction
<b>Required Medical Information</b>	Diagnosis. Must have a diagnosis of primary biliary cholangitis (PBC) defined by meeting at least two of the following criteria: 1) chart doc of lab result showing elevated alkaline phosphatase (ALP) above the upper limit of normal (ULN) for at least 6 months based on the reference range provided by lab, 2) positive anti-mitochondrial antibody (AMA) titer, 3) liver biopsy consistent with PBC. Must have an adequate trial of at least 12 months with ursodiol at a dose of 13-15 mg/kg/day with an inadequate response (defined as ALP 1.5-times the ULN) or intolerance at any dose or must have a contraindication to ursodiol. Must be used in combination with ursodiol unless clinically contraindicated or intolerant to ursodiol. For reauth: Must have documentation from provider showing disease has improved while on therapy and monitoring of liver function tests occurring annually.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a gastroenterologist, hepatologist, or liver transplant specialist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ODOMZO
<b>Drug Names</b>	ODOMZO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ONFI
<b>Drug Names</b>	ONFI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Lennox-Gastaut syndrome. Must have had an inadequate response or intolerance to 2 generic antiepileptic drugs (e.g. lamotrigine, topiramate, felbamate) and be using clobazam as adjunctive therapy to other anti-epileptic drugs.
<b>Age Restrictions</b>	Age 2 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a neurologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ONMEL
<b>Drug Names</b>	ONMEL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Immunocompromised member
<b>Required Medical Information</b>	Diagnosis. Must have onychomycosis of toenail due to Trichophyton rubrum or T. mentagrophytes causing severe, debilitating foot pain supported by chart documentation. Must provide chart documentation of laboratory testing of nail specimen (such as KOH preparation, fungal culture, or nail biopsy). Must have documentation of trial and failure of itraconazole capsules for at least 1 full course of treatment (3 months). For reauth: based upon diagnosis and must have documentation of response to previous course of treatment with itraconazole tablets (Onmel).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	90 days
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	OPSUMIT
<b>Drug Names</b>	OPSUMIT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of PAH (WHO Group I) confirmed by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have baseline hemoglobin and liver function tests (AST, ALT) prior to initiation of therapy. Must have baseline negative pregnancy prior to initiation of therapy if a female of child-bearing potential. Must have previous inadequate response or intolerance to ambrisentan (Letairis). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ORALAIR
<b>Drug Names</b>	ORALAIR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	History of any severe systemic allergic reaction. History of eosinophilic esophagitis. Severe, unstable or uncontrolled asthma. On concomitant immunotherapy.
<b>Required Medical Information</b>	Diagnosis. Must have moderate to severe grass pollen-induced allergic rhinitis with or without conjunctivitis. Must have diagnosis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens (i.e. Sweet Vernal, Orchard, Perennial Rye, Kentucky Blue Grass) and chart documentation demonstrating seasonal symptoms to grass-pollen from the previous pollen season. Must have chart documentation demonstrating daily concomitant use of an inhaled nasal corticosteroid (i.e. fluticasone) and an oral antihistamine (i.e. levocetirizine) during the previous pollen season with inadequate responses or significant side effects/toxicities or have contraindication to these therapies. Must have plan for first dose to be administered in physician office due to potential for life-threatening allergic reactions, including anaphylaxis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 10 years through 65 years
<b>Prescriber Restrictions</b>	Allergist or immunologist
<b>Coverage Duration</b>	180 days
<b>Other Criteria</b>	Therapy must be initiated 4 months prior to the onset of grass pollen season.

<b>Prior Authorization Group</b>	ORFADIN
<b>Drug Names</b>	ORFADIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Hereditary Tyrosinemia Type 1. Laboratory test of baseline succinylacetone (SA) level, liver evaluation, and ophthalmologic testing. For reauth: must have documentation from prescriber indicating improvement in condition, monitoring for hematologic and hepatic side effects, and laboratory test demonstrating progressive SA suppression.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a gastroenterologist, hematologist, nephrologist, or physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ORFADIN SUSPENSION
<b>Drug Names</b>	ORFADIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of Hereditary Tyrosinemia Type 1. Laboratory test of baseline succinylacetone (SA) level, liver evaluation, and ophthalmologic testing. Must have chart documentation of the clinical rationale for why nitisinone capsule cannot be used. For reauth: must have documentation from prescriber indicating improvement in condition, monitoring for hematologic and hepatic side effects, and laboratory test demonstrating progressive SA suppression.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a gastroenterologist, hematologist, nephrologist, or physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ORKAMBI
<b>Drug Names</b>	ORKAMBI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Documentation of lab result confirming the following mutation in CFTR gene: F508del. Baseline percent of predicted FEV1. For reauth: must have chart documentation from prescriber showing member benefit from treatment, clinical rationale to support continuation of therapy, and current percent predicted FEV1.
<b>Age Restrictions</b>	Age 6 years or older
<b>Prescriber Restrictions</b>	Cystic Fibrosis specialist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	OTREXUP AND RASUVO
<b>Drug Names</b>	OTREXUP, RASUVO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have an adequate trial of oral methotrexate or generically-available subcutaneous methotrexate with an inadequate response OR have had a significant side effect/toxicity. For Otrexup requests must have an adequate trial of Rasuvo with an inadequate response OR have had a significant side effect/toxicity. For reauth: must have documentation from the prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	RA, psoriatic JIA: rheumatologist. Psoriasis: dermatologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	OXANDROLONE - PENDING CMS REVIEW
<b>Drug Names</b>	OXANDROLONE
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	

<b>Prior Authorization Group</b>	PALIPERIDONE
<b>Drug Names</b>	PALIPERIDONE ER
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of schizophrenia or schizoaffective disorder. Must have adequate trial and failure of 2 oral atypical antipsychotics.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	PANRETIN
<b>Drug Names</b>	PANRETIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must be on an antiretroviral regimen. For reauth: must have documentation from prescriber indicating stabilization or improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a dermatologist, oncologist, or HIV specialist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	PHEOCHROMOCYTOMA
<b>Drug Names</b>	DEMSEER
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have surgical resection planned, have a contraindication to surgery, or have malignant pheochromocytoma. For reauth: must have documentation from prescriber indicating stabilization or improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a nephrologist, oncologist, endocrinologist, or endocrine surgeon
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	PICATO
<b>Drug Names</b>	PICATO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Initial auth: actinic keratosis must be present on face, scalp, trunk, or extremities and pt must have adequate trial of topical fluorouracil or imiquimod 5% with inadequate response unless intolerant or contraindicated. For reauth: must meet initial auth criteria and must have either clinical rationale from the prescriber for continuation of treatment at the same site or documentation that therapy is required at an alternative site.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a dermatologist or oncologist
<b>Coverage Duration</b>	3 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	POMALYST
<b>Drug Names</b>	POMALYST
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	PRALUENT
<b><i>Drug Names</i></b>	PRALUENT
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. Must have confirmed diagnosis of heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD). For ASCVD: must have chart documentation confirming history of at least one of the following: myocardial infarction or other acute coronary syndromes (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina), coronary or other revascularization procedure, ischemic stroke or transient ischemic attack, atherosclerotic peripheral arterial disease (includes ankle/brachial index of less than 0.90), coronary artery calcium greater than or equal to 300 Agatston units or greater than or equal to 75th percentile for age/sex/ethnicity, carotid plaque greater than or equal to 50%, coronary atherosclerosis as demonstrated by angiography (cardiac CT angiography or conventional cardiac catheterization). Must have baseline and target LDL-cholesterol levels. Must have LDL-C level above target despite adequate trial of 2 high intensity statins (atorvastatin 40-80mg daily and rosuvastatin 20-40mg daily), unless intolerant to statin treatment (defined as confirmed, intolerable statin-related adverse effects or biomarker abnormalities that improve or resolve with statin dose decrease or discontinuation) or statin treatment is contraindicated (defined as documented active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels). If able to tolerate statin, must continue treatment with statin at maximally tolerated dose. For reauth: must have documentation of: (1) recent assessment of LDL-C level with decrease and (2) continued treatment with maximally tolerated dose of a statin (if applicable).
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	By or in consultation with a cardiologist or an endocrinologist
<b><i>Coverage Duration</i></b>	Initial: 90 days. Reauth: 365 days.
<b><i>Other Criteria</i></b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	PROLIA
<b><i>Drug Names</i></b>	PROLIA
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. Must have trial and failure of bisphosphonate therapy unless intolerant or contraindicated. For postmenopausal osteoporosis in females or to increase bone mass in males with osteoporosis at high risk of fracture: must have bone mineral density T-score of less than or equal to -2.5 at conventional skeletal sites including the total hip, femoral neck, lumbar spine (post-anterior, not lateral) or radius OR must have history of fragility fracture as an adult. For females with breast cancer: must be receiving aromatase inhibitor therapy. For males with non-metastatic prostate cancer: must be receiving androgen deprivation therapy. For reauth: must have documentation from prescriber indicating improvement in condition.
<b><i>Age Restrictions</i></b>	Age 18 years or older
<b><i>Prescriber Restrictions</i></b>	No Prescriber Restrictions
<b><i>Coverage Duration</i></b>	365 Days
<b><i>Other Criteria</i></b>	Not Applicable

<b>Prior Authorization Group</b>	PROMACTA
<b>Drug Names</b>	PROMACTA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For ITP: must have platelet count less than 30,000. For thrombocytopenia associated with chronic Hepatitis C: must have platelet count of less than 75,000 and currently be on treatment with or anticipating hepatitis C treatment with interferon product. For aplastic anemia: must have severe disease, must have platelet count less than 30,000, and must have previous inadequate response or intolerance to antithymocyte globulin-based immunosuppressive therapy (Atgam, Thymoglobulin). For reauth: must have documentation from prescriber indicating improvement in condition (all dx), improvement in platelet count from baseline (all dx), and hematologic response (aplastic anemia dx: increase in platelet count, increase in Hgb, increase in ANC, reduction in frequency of platelet or RBC transfusions). In addition, eltrombopag tx should be discontinued for any of the following: if platelet count does not increase to sufficient level to avoid clinically important bleeding after 4 weeks of tx max daily dose of 75mg (ITP dx only) or 150mg (aplastic anemia dx only), if ALT levels increase to greater than or equal to 3x upper limit of normal and are any of the following (progressive, persistent for at least 4 weeks, accompanied by increased direct bilirubin, accompanied by clinical symptoms of liver injury or evidence of hepatic decompensation), if platelet count is greater than 400,000 after 2 weeks of therapy at lowest eltrombopag dose, when antiretroviral therapy is discontinued (Hep C dx only).
<b>Age Restrictions</b>	ITP: age 1 year or older. Other diagnoses: age 18 years or older.
<b>Prescriber Restrictions</b>	ITP, aplastic anemia: hematologist or oncologist. Hep C: gastroenterologist, hematologist, or hepatologist.
<b>Coverage Duration</b>	90 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	PULMOZYME
<b>Drug Names</b>	PULMOZYME
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of cystic fibrosis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	365 Days
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	PURIXAN
<b>Drug Names</b>	PURIXAN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have a trial and failure of mercaptopurine tablets or have chart documentation of the clinical rationale for why the tablet version cannot be used.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a hematologist or an oncologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	QUETIAPINE
<b>Drug Names</b>	QUETIAPINE FUMARATE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	QUETIAPINE ER
<b>Drug Names</b>	QUETIAPINE FUMARATE ER
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For schizophrenia, bipolar disorder: must have previous trial and failure of immediate-release quetiapine. For major depressive disorder: must have adequate trial and failure (duration at least 4 weeks) with 2 different antidepressant therapies (e.g. SSRIs, SNRIs) with inadequate responses or intolerance.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	QUININE
<b>Drug Names</b>	QUININE SULFATE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of malaria. For reauth: must have documentation from prescriber indicating continued benefit from therapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 Days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	RAGWITEK
<b>Drug Names</b>	RAGWITEK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	History of any severe systemic allergic reaction. History of eosinophilic esophagitis. Severe, unstable or uncontrolled asthma. On concomitant immunotherapy.
<b>Required Medical Information</b>	Diagnosis. Must have moderate to severe short ragweed pollen-induced allergic rhinitis with or without conjunctivitis. Must have diagnosis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen and chart documentation demonstrating seasonal symptoms to ragweed-pollen from the previous pollen season. Must have chart documentation demonstrating daily concomitant use of an inhaled nasal corticosteroid (i.e. fluticasone) and an oral antihistamine (i.e. levocetirizine) during the previous pollen season with inadequate responses or significant side effects/toxicities or have contraindication to these therapies. Must have plan for first dose to be administered in physician office due to potential for life threatening allergic reactions, including anaphylaxis. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Allergist or immunologist
<b>Coverage Duration</b>	180 days
<b>Other Criteria</b>	Therapy must be initiated 12 weeks prior to the onset of short ragweed pollen season.

<b>Prior Authorization Group</b>	RAVICTI
<b>Drug Names</b>	RAVICTI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation describing how diagnosis was confirmed (e.g. genetic testing results, enzyme assays, ammonia levels, progress notes, etc.). Must have chart documentation of an adequate trial of sodium phenylbutyrate with either inadequate response despite dose titration or significant side effect/toxicity or have a contraindication to this therapy. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with physician who specializes in the treatment of inherited metabolic disorders.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	REGRANEX
<b>Drug Names</b>	REGRANEX
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Neoplasm at site of application
<b>Required Medical Information</b>	Diagnosis. For treatment of diabetic neuropathic ulcers, patient must have a lower extremity diabetic neuropathic ulcer. Treatment will be given in combination with ulcer wound care (i.e. debridement, infection control, and/or pressure relief). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	20 weeks
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	RELISTOR
<b>Drug Names</b>	RELISTOR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For opioid-induced constipation and advanced life-limiting illness: must have documentation of previous trial of lactulose. For opioid-induced constipation with chronic non-cancer pain: must have documentation of current and ongoing opioid therapy and must have adequate trials of 2 of the following with inadequate responses or significant side effects/toxicity or have a contraindication to these therapies: naloxegol (Movantik), lubiprostone (Amitiza), or lactulose. For reauth: must have documentation from prescriber indicating improvement in condition (both diagnoses) and must continue to be on opioid therapy (non-cancer pain).
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Initial: 90 days (non-cancer pain), 120 days (life-limiting illness). Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	RELISTOR TABLET
<b>Drug Names</b>	RELISTOR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have documentation of current and ongoing opioid therapy and must have adequate trials of naloxegol (Movantik) and lubiprostone (Amitiza) with inadequate responses or significant side effects/toxicity or have a contraindication to these therapies. For reauth: must have documentation from prescriber indicating improvement in condition (both diagnoses) and must continue to be on opioid therapy.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Initial: 90 days Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	REMICADE
<b>Drug Names</b>	REMICADE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. Use of TNF-blocking or other biologic agent in combination with infliximab.
<b>Required Medical Information</b>	Diagnosis. Current patient weight (within the last 3 months), dosage and frequency of infusions. Negative TB skin test. For plaque psoriasis: must have chronic moderate to severe disease. For ankylosing spondylitis: must have active disease. For all other dx: must have moderately to severely active disease. For RA: adequate trial of methotrexate with inadeq response (if significant side effects/toxicity or contraindication to methotrexate must have adequate trial of hydroxychloroquine, leflunomide, or sulfasalazine). For psoriatic arthritis (peripheral disease): must have an adequate trial of 1 NSAID at target anti-inflammatory dose and of 1 conventional systemic therapy (e.g. methotrexate, cyclosporine, leflunomide, sulfasalazine) with inadeq responses or significant side effects/toxicities unless contraindicated. For psoriatic arthritis (axial, skin, nail, enthesitis, or dactylitis dominant): must have an adequate trial of 2 NSAIDs at target anti-inflammatory dose with inadeq response or sig. side effects/toxicities unless contraindicated. For ankylosing spondylitis: adequate trial of 2 NSAIDs at target anti-inflammatory dose with inadeq response or significant side effects/toxicity or have a contraindication. For plaque psoriasis: minimum BSA involvement of at least 5% (not required if on palms, soles, head/neck, genitalia), adequate trial of 1 topical treatment or phototherapy or photochemotherapy with inadeq response or significant side effects/toxicity unless contraindicated, and adequate trial of 1 conventional systemic therapy (e.g. methotrexate, acitretin, cyclosporine) with inadeq response or significant side effects/toxicity unless contraindicated. For Crohn's, UC: adequate trial of 1 conventional therapy incl corticosteroid, 5-ASA agent (UC only), or immunosuppressant with inadeq response or significant side effects/toxicity unless contraindicated. For reauth: documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Crohn's, UC: age 6 years or older. Other dx: age 18 years and older
<b>Prescriber Restrictions</b>	RA, ankylosing spondylitis: rheumatologist. Psoriatic arthritis: rheumatologist, dermatologist. Plaque psoriasis: dermatologist. Crohn's, UC: gastroenterologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Dose and frequency of infusions should be in accordance with the FDA label. When doses are requested in excess of established FDA parameters, they will be subject to review for medical necessity.

<b><i>Prior Authorization Group</i></b>	REMODULIN
<b><i>Drug Names</i></b>	REMODULIN
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have WHO Functional Class II-IV symptoms. For reauth: must have documentation from prescriber indicating improvement in condition.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	Pulmonary hypertension specialist
<b><i>Coverage Duration</i></b>	Initial: 90 days. Reauth: 365 days.
<b><i>Other Criteria</i></b>	Not Applicable

<b>Prior Authorization Group</b>	REPATHA
<b>Drug Names</b>	REPATHA, REPATHA PUSHTRONEX SYSTEM, REPATHA SURECLICK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have confirmed diagnosis of heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH, see Other Criteria section) or clinical atherosclerotic cardiovascular disease (ASCVD, see Other Criteria section). Must have baseline and target LDL-cholesterol levels. Must have LDL-C level above target despite adequate trial of 2 high intensity statins (atorvastatin 40-80mg daily and rosuvastatin 20-40mg daily), unless intolerant to statin treatment (defined as confirmed, intolerable statin-related adverse effects or biomarker abnormalities that improve or resolve with statin dose decrease or discontinuation) or statin treatment is contraindicated (defined as documented active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels). If able to tolerate statin, must continue treatment with statin at maximally tolerated dose. For reauth: must have documentation of: (1) recent assessment of LDL-C level with decrease and (2) continued treatment with maximally tolerated dose of a statin (if applicable).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a cardiologist or an endocrinologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	HoFH: must be confirmed by genetic testing with functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality or have clinical diagnosis defined as one of the following (1) untreated LDL greater than 500mg/dL AND untreated total cholesterol (TC) greater than 500mg/dL and triglycerides (TG) less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (2) skin fibroblast LDL receptor activity less than 20% of normal AND untreated TC greater than 500mg/dL and TG less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (3) presence of cutaneous and tendon xanthomas and corneal arcus in first decade of life AND untreated TC greater than 500mg/dL and TG less than 300mg/dL with both parents with untreated TC greater than 250mg/dL, (4) untreated LDL greater than 500mg/dL AND skin fibroblast LDL receptor activity less than 20% of normal, (5) untreated LDL greater than 500mg/dL AND presence of cutaneous and tendon xanthomas and corneal arcus in first decade of life. For ASCVD: must have chart documentation confirming history of at least one of the following: myocardial infarction or other acute coronary syndromes (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina), coronary or other revascularization procedure, ischemic stroke or transient ischemic attack, atherosclerotic peripheral arterial disease (includes ankle/brachial index of less than 0.90), coronary artery calcium greater than or equal to 300 Agatston units or greater than or equal to 75th percentile for age/sex/ethnicity, carotid plaque greater than or equal to 50%, coronary atherosclerosis as demonstrated by angiography (cardiac CT angiography or conventional cardiac catheterization).

<b>Prior Authorization Group</b>	REVLIMID
<b>Drug Names</b>	REVLIMID
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	REXULTI
<b>Drug Names</b>	REXULTI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For Major Depressive Disorder: must have adequate trial and failure or inadequate response or intolerance to aripiprazole and must be on concomitant therapy with an SSRI or SNRI as adjunctive treatment. For Schizophrenia: must have an adequate trial and failure or inadequate response or intolerance to 2 generic oral atypical antipsychotics (e.g. aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	RITUXAN
<b>Drug Names</b>	RITUXAN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of severe active infection. Use of TNF-blocking or other biologic agent in combination with rituximab. PML or history of PML. Use of rituximab for maintenance therapy for Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
<b>Required Medical Information</b>	Diagnosis. For RA: must have moderate to severe RA, must be on concurrent methotrexate therapy, must have adequate trials of etanercept and adalimumab with inadequate responses or significant side effects/toxicities unless contraindicated. For Wegener's Granulomatosis and Microscopic Polyangiitis: must be used as induction therapy for remission, must be on concomitant therapy w/ glucocorticoids. For reauth: must have doc from prescriber indicating improvement in condition (RA, cancer).
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	RA, Wegeners, Microscopic Polyangiitis: rheumatologist. Cancer: hematologist, oncologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	This criteria is for non-antineoplastic use only. For the treatment of cancer diagnoses, the medication will be covered under either the Part B or Part D plan in accordance with CMS regulations. For WG and MPA, additional courses will not be authorized.

<b>Prior Authorization Group</b>	RUBRACA
<b>Drug Names</b>	RUBRACA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming BRCA mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	RYDAPT
<b>Drug Names</b>	RYDAPT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For acute myeloid leukemia: must have chart documentation of lab result confirming FLT3 mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SABRIL
<b>Drug Names</b>	SABRIL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must undergo vision testing prior to beginning treatment. For Refractory Complex Partial Seizures: must have inadequate response to 2 combination anticonvulsant regimens (at least 1 of the regimens must contain phenytoin or carbamazepine), must be using in combination with at least 1 other anticonvulsant medication. For reauth: must have documentation from prescriber indicating improvement in condition and that member is undergoing vision testing at least every 3 months during treatment with vigabatrin.
<b>Age Restrictions</b>	Seizure: age 10 years or older. Infantile spasms: age 1 month to 2 years.
<b>Prescriber Restrictions</b>	Neurologist or pediatric neurologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	For infantile spasms will not be extended beyond the age of 2 years.
<b>Prior Authorization Group</b>	SAMSCA
<b>Drug Names</b>	SAMSCA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Anuria, on concomitant therapy with a strong CYP3A inhibitor, underlying liver disease (including cirrhosis), hypovolemic hyponatremia
<b>Required Medical Information</b>	Diagnosis. Must have serum sodium less than 125mEq/L OR symptomatic hyponatremia that resisted correction with 72 hours of both of the following interventions: (1)fluid restriction of less than 1000mL/day and (2)consideration of discontinuation of agents known to cause SIADH when clinically feasible (e.g. chlorpropamide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, clofibrate, carbamazepine, vincristine, nicotine, narcotics, antipsychotic drugs, ifosfamide, cyclophosphamide, NSAIDs, MDMA, desmopressin, oxytocin, vasopressin). Must have CrCl greater than 10mL/min. Must be initiated and titrated in hospital setting with close serum sodium monitoring. Must be able to sense and appropriately respond to thirst. If SIADH is underlying cause of hyponatremia, must provide chart documentation of clinical work-up to rule out other diagnoses and clinical rationale for diagnosis and exclusion of other diagnoses (must demonstrate all of the following: decreased plasma osmolality of less than 275 mosm/kg, increased urinary osmolality of greater than 100mosm/kg during hypotonicity, urinary sodium greater than 20mmol/L with normal dietary salt intake, clinical euvoemia, normal thyroid and adrenal function, and no recent use of antidiuretics within 24 hours of laboratory testing.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Endocrinologist or nephrologist
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	Due to risk of liver injury, tolvaptan should not be administered for more than 30 days.

<b>Prior Authorization Group</b>	SANDOSTATIN LAR
<b>Drug Names</b>	SANDOSTATIN LAR DEPOT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For acromegaly: must have inadequate response to surgery or radiation therapy or have documentation that these therapies are inappropriate AND must have confirmed diagnosis with elevated serum IGF-1 for age/gender (must provide lab reference range) and elevated growth hormone level greater than or equal to 1ng/mL during oral glucose tolerance test. For severe diarrhea and flushing episodes: must be associated with metastatic carcinoid tumor. For profuse watery diarrhea: must be associated with vasoactive intestinal peptide secreting tumor. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with an endocrinologist, hematologist, oncologist, gastroenterologist, or palliative care specialist depending upon diagnosis.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SAPHRIS
<b>Drug Names</b>	SAPHRIS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have tried and failed 2 atypical antipsychotics.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SAVELLA
<b>Drug Names</b>	SAVELLA, SAVELLA TITRATION PACK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation showing history of widespread pain involving the extremities for 3 months and localized areas of tenderness. Must have chart documentation or claims history showing a trial of gabapentin at a dose of at least 1200mg/day with inadequate response or significant side effects/toxicity despite slow dose titration or have a contraindication to this therapy. Must have chart documentation or claims history showing a trial of a tricyclic antidepressant (e.g. amitriptyline) or muscle relaxant (e.g. cyclobenzaprine) with inadequate response or significant side effects/toxicity or have a contraindication to these therapies.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SEROSTIM - PENDING CMS REVIEW
<b>Drug Names</b>	SEROSTIM
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	

<b>Prior Authorization Group</b>	SIGNIFOR
<b>Drug Names</b>	SIGNIFOR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of confirmed pituitary source of Cushing's syndrome. Must previously have had pituitary surgery (e.g. transsphenoidal surgery) that was not curative unless not a candidate for surgery. Must have baseline 24-hour urinary free cortisol level. Must have recent (within 6 months) baseline assessments of fasting plasma glucose, liver function tests, electrocardiogram, gallbladder ultrasound, pituitary hormones (e.g. TSH, free T4, growth hormone, IGF-1), and hemoglobin A1C. Must provide chart documentation of optimized anti-diabetic therapy if baseline hemoglobin A1C is greater than 8%. For reauth: must have documentation from prescriber indicating improvement in condition based on reduction in 24-hour urinary free cortisol level from baseline level as well as signs and symptoms of improvement in the disease (e.g. blood pressure, lipids, weight) and must have documentation that hemoglobin A1C, fasting plasma glucose, liver function tests, gallbladder ultrasound, pituitary hormones, and electrocardiogram have all been reassessed within 3 months of starting pasireotide and at regular intervals thereafter.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with an endocrinologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SIGNIFOR LAR
<b>Drug Names</b>	SIGNIFOR LAR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of acromegaly. Must have following baseline labs: elevated serum IGF-1 level for gender/age range (including lab reference range) and elevated growth hormone level (defined as GH at least 1ng/mL during oral glucose tolerance test). Must have inadequate response to surgery or radiation therapy or documentation that these therapies are inappropriate. Must have recent (within 6 months) baseline assessment of hemoglobin A1C. Must provide chart documentation of optimized anti-diabetic therapy if baseline hemoglobin A1C is greater than 8%. Must have a previous trial of octreotide acetate (Sandostatin LAR) or lanreotide (Somatuline Depot) with an inadequate response or intolerance. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with an endocrinologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SILDENAFIL
<b>Drug Names</b>	REVATIO, SILDENAFIL
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Current use of nitrate product
<b>Required Medical Information</b>	Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have WHO Functional Class II-IV symptoms. For sildenafil suspension: must have chart documentation of the clinical rationale for why sildenafil tablet cannot be used. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SIROLIMUS
<b>Drug Names</b>	RAPAMUNE, SIROLIMUS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Must have diagnosis of lymphangioleiomyomatosis or prophylaxis of organ rejection. For prophylaxis of organ rejection, must have undergone solid organ transplant and must have at least one of the following: renal dysfunction, coronary allograft vasculopathy following heart transplant, OR trial and failure (defined as intolerance to regimen or inability of regimen to prevent rejection at appropriate therapeutic dosing) of anti-rejection regimen containing at least 2 drugs (including cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolate sodium).
<b>Age Restrictions</b>	Prophylaxis of organ rejection: age 13 years or older. Lymphangioleiomyomatosis: age 18 years or older.
<b>Prescriber Restrictions</b>	Prophylaxis of organ rejection: by or in consultation with a transplant specialist. Lymphangioleiomyomatosis: pulmonologist, hematologist, or oncologist.
<b>Coverage Duration</b>	365 Days
<b>Other Criteria</b>	B vs. D determination will be made prior to clinical criteria being applied.

**Prior Authorization Group** SIRTURO - PENDING CMS REVIEW  
**Drug Names** SIRTURO  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** SKELETAL MUSCLE RELAXANTS  
**Drug Names** CARISOPRODOL, CARISOPRODOL/ASPIRIN, CARISOPRODOL/ASPIRIN/CODE,  
CHLORZOXAZONE, CYCLOBENZAPRINE HCL, METHOCARBAMOL,  
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE ER  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis. Must have attestation from prescriber assessing the risks and benefits of  
therapy and desire to prescribe a muscle relaxant.  
**Age Restrictions** Age 65 years or older: criteria apply. Age less than 65 years: criteria do not apply.  
**Prescriber Restrictions** No Prescriber Restrictions  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

**Prior Authorization Group** SODIUM PHENYLBUTYRATE  
**Drug Names** BUPHENYL, SODIUM PHENYLBUTYRATE  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis. Must have chart documentation describing how diagnosis was confirmed  
(e.g. genetic testing results, enzyme assays, ammonia levels, progress notes, etc.). For  
reauth: must have documentation from prescriber indicating improvement in condition.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** By or in consultation with a hematologist, nephrologist, or physician who specializes in  
the treatment of inherited metabolic disorders.  
**Coverage Duration** Initial: 90 days. Reauth: 365 days.  
**Other Criteria** Not Applicable

<b>Prior Authorization Group</b>	SOMATULINE DEPOT
<b>Drug Names</b>	SOMATULINE DEPOT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For acromegaly: must have baseline labs (elevated serum IGF-1 level for gender/age range, including lab reference range, and elevated growth hormone level defined as GH at least 1ng/mL during oral glucose tolerance test), must have inadequate response to surgery or radiation therapy or documentation that these therapies are inappropriate. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Acromegaly: by or in consultation with an endocrinologist. GEP-NETs: by or in consultation with a hematologist, an oncologist, an endocrinologist, or a palliative care specialist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SOMAVERT
<b>Drug Names</b>	SOMAVERT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of acromegaly. Must have following baseline labs: elevated serum IGF-1 level for gender/age range (including lab reference range) and elevated growth hormone level defined as GH at least 1ng/mL during oral glucose tolerance test. Must have inadequate response to surgery or radiation therapy or documentation that these therapies are inappropriate. Must have inadequate response to 1 medical therapy (e.g. octreotide, octreotide LAR, lanreotide) or documentation that these therapies are inappropriate. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with an endocrinologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable



**Prior Authorization Group** SOVALDI - PENDING CMS REVIEW  
**Drug Names** SOVALDI  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** SPRITAM  
**Drug Names** SPRITAM  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis. Must have had an inadequate response or intolerance to generic levetiracetam and one other generic antiepileptic drug (such as carbamazepine, oxcarbazepine, or phenytoin) and be using levetiracetam (Spritam) as adjunctive therapy to other antiepileptic drugs (which can include medications from trials above).  
**Age Restrictions** Age 4 years or older  
**Prescriber Restrictions** By or in consultation with a neurologist.  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

**Prior Authorization Group** SPRYCEL  
**Drug Names** SPRYCEL  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** Oncologist or hematologist  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

<b>Prior Authorization Group</b>	STIVARGA - PENDING CMS REVIEW
<b>Drug Names</b>	STIVARGA
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	
<b>Prior Authorization Group</b>	STRENSIQ
<b>Drug Names</b>	STRENSIQ
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have an onset of symptoms prior to age 18. Reauth: must have chart documentation of improvement in the member's condition, including skeletal manifestations.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with an endocrinologist, geneticist, or metabolic disorders specialist
<b>Coverage Duration</b>	Initial: 180 days. Reauth: 365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	SUBOXONE AND SUBUTEX - PENDING CMS REVIEW
<b>Drug Names</b>	BUPRENORPHINE HCL, BUPRENORPHINE HCL/NALOXON, SUBOXONE
<b>Covered Uses</b>	
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	
<b>Other Criteria</b>	

<b>Prior Authorization Group</b>	SUCRAID
<b>Drug Names</b>	SUCRAID
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For congenital sucrase-isomaltase deficiency: must have low sucrase activity on duodenal biopsy with other disaccharidases normal on same duodenal biopsy OR must have stool pH less than 6, increase in breath hydrogen of greater than 10ppm when challenged with sucrose after fasting, and negative lactose breath test. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 5 months or older
<b>Prescriber Restrictions</b>	Gastroenterologist, endocrinologist, or metabolic specialist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SUTENT
<b>Drug Names</b>	SUTENT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SYLVANT
<b>Drug Names</b>	SYLVANT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. HIV or HHV 8 positive
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation demonstrating a history of (1)lymphadenopathy in greater than one lymph node site and (2)constitutional symptoms such as fever, night sweats, significant weight loss, fatigue, weakness, anorexia, anemia.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SYNAGIS
<b>Drug Names</b>	SYNAGIS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. If under age 12 mo at start of RSV season w/ no other medical dx: must have gestational age (GA) less than 29 wks. If under age 24 mo at start of RSV season during 1st year of life w/ Chronic Lung Disease (CLD) of prematurity: must have GA less than 32 weeks 0 days AND required greater than 21% oxygen (O2) for at least first 28 days of life. If under age 24 mo at start of RSV season during 2nd year of life w/ CLD of prematurity: must have GA less than 32 weeks 0 days AND required greater than 21% O2 for at least first 28 days of life AND have continued to require medical support (chronic corticosteroid therapy, diuretic therapy, supplemental O2) during 6 months before start of 2nd RSV season. If under age 12 mo at start of RSV season w/ heart disease: must have hemodynamically significant Congenital Heart Disease (CHD) (and be on drugs to control heart failure) OR have acyanotic heart disease (and be on drugs to control heart failure and require cardiac surgery) OR have mod-sev pulm HTN OR have cardiac lesions adequately corrected by surgery (and still continue to be on drugs for heart failure). If under age 12 mo at start of RSV season w/ neuromuscular disease or congenital anomaly: must demonstrate that disease/anomaly impairs ability to clear secretions from upper airway b/c of ineffective cough. If under age 24 mo at start of RSV season and profoundly immunocompromised: must have doc of reason (e.g. severe combined immunodeficiency, severe T-cell deficiency, severe AIDS, AML, acute lymphoblastic leukemia, receiving chemotx, received hematopoietic SCT). If under age 24 mo w/ cystic fibrosis (CF): during 1st year of life must have clinical evidence of CLD and/or nutritional compromise OR during 2nd year of life must have manifestation of severe lung disease (prior hospitalization for pulmonary exacerbation in 1st year of life, abnormalities on chest radiography/CT that persist when stable, weight for length is less than 10th %).
<b>Age Restrictions</b>	Less than 12 months or less than 24 months of age at start of RSV season depending on criteria
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Maximum of 5 doses per RSV season.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	SYPRINE
<b>Drug Names</b>	SYPRINE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of how diagnosis was confirmed including at least one of the following: hepatic parenchymal copper content greater than or equal to 250 micrograms per gram dry weight, presence of Kayser-Fleischer Ring in cornea, serum ceruloplasmin level less than 50mg/L, basal 24-hour urinary excretion of copper greater than 100 micrograms (1.6 millimoles), or genetic testing indicating mutation in ATP7B gene. Must have adequate trial of penicillamine (Depen) with an inadequate response or significant side effects/toxicity or must have a contraindication to this therapy. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a gastroenterologist, ophthalmologist, or physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	Initial: 90 days. Reauth 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TABLOID
<b>Drug Names</b>	TABLOID
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TAFINLAR
<b>Drug Names</b>	TAFINLAR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming BRAFV600E or BRAFV600K mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TAGRISSE
<b>Drug Names</b>	TAGRISSE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming epidermal growth factor receptor (EGFR) T790M mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TARCEVA
<b>Drug Names</b>	TARCEVA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For 1st-line treatment of patients w/ metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations: must have chart documentation of laboratory result confirming EGFR mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TARGRETIN
<b>Drug Names</b>	BEXAROTENE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TASIGNA
<b>Drug Names</b>	TASIGNA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TCA
<b>Drug Names</b>	AMITRIPTYLINE HCL, CLOMIPRAMINE HCL, DOXEPIN HCL, IMIPRAMINE HCL, IMIPRAMINE PAMOATE, TRIMIPRAMINE MALEATE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D and urticaria for doxepin
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Approve amitriptyline, doxepin (doses higher than 6mg/day), imipramine, or trimipramine if prior trial and failure of 2 of following for depression: SSRIs, venlafaxine, venlafaxine ER capsules, nortriptyline, desipramine, trazodone, mirtazapine, bupropion. Approve clomipramine if prior trial and failure of 2 of following for obsessive-compulsive disorder: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, venlafaxine ER capsules. Approve doxepin for urticaria if prior trial and failure of levocetirizine. For all other FDA-approved indications, no prior drug trials are required.
<b>Age Restrictions</b>	Age 65 years or older: criteria apply. Age less than 65 years: criteria do not apply.
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	TETRABENAZINE
<b>Drug Names</b>	TETRABENAZINE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Actively suicidal. Uncontrolled depression. Currently using a monoamine oxidase inhibitor or reserpine. Hepatic impairment.
<b>Required Medical Information</b>	Diagnosis. Must have confirmed Huntington's disease either by Huntington Disease Mutation analysis (with laboratory result indicating expanded CAG repeat of greater than or equal to 36 in the huntington gene) or a positive family history of Huntington's Disease with autosomal dominant inheritance pattern. Must have clinical signs of Huntington's Disease to include chart documentation of a clinical work-up showing one or more of the following signs: motor (e.g. finger tapping, rigidity), oculomotor, bulbar (e.g. dysarthria, dysphagia), affective (e.g. depression), cognitive. Must have chart documentation of chorea associated with Huntington's Disease. For doses greater than 50mg/day: must have chart documentation of an adequate trial of 50mg/day dose with inadequate response OR must be CYP2D6 intermediate or extensive metabolizer (as documented through CYP2D6 genotyping results), must provide documentation of slow dose titration with close monitoring of side effects. For reauth: must have documentation from the prescriber indicating improvement in condition and showing monitoring for depression and suicidal ideation. For reauth for doses greater than 50mg/day: must have chart documentation from prescriber showing inadequate efficacy of lower doses and slow titration of dose with close monitoring of side effects.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Maximum dose approved is 100mg/day.

<b>Prior Authorization Group</b>	THALOMID
<b>Drug Names</b>	THALOMID
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable



**Prior Authorization Group** THIOLA - PENDING CMS REVIEW  
**Drug Names** THIOLA  
**Covered Uses**  
**Exclusion Criteria**  
**Required Medical Information**  
**Age Restrictions**  
**Prescriber Restrictions**  
**Coverage Duration**  
**Other Criteria**

**Prior Authorization Group** TRACLEER  
**Drug Names** TRACLEER  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** Current use of glyburide or cyclosporine  
**Required Medical Information** Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have WHO Functional Class II-IV symptoms. For patients with WHO Functional Class II and III symptoms: must have previous inadequate response or intolerance to ambrisentan (Letairis). Must have baseline liver function tests (AST, ALT), prior to initiation of therapy. Must have baseline negative pregnancy test prior to initiation of therapy if a female of child-bearing potential. For reauth: must have documentation from prescriber indicating improvement in condition.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.  
**Coverage Duration** Initial: 90 days. Reauth: 365 days.  
**Other Criteria** Not Applicable

**Prior Authorization Group** TYKERB  
**Drug Names** TYKERB  
**Covered Uses** All FDA-approved indications not otherwise excluded from Part D  
**Exclusion Criteria** No Exclusion Criteria  
**Required Medical Information** Diagnosis. ECOG Performance Status.  
**Age Restrictions** No Age Restrictions  
**Prescriber Restrictions** Oncologist or hematologist  
**Coverage Duration** 365 days  
**Other Criteria** Not Applicable

<b>Prior Authorization Group</b>	UPTRAVI
<b>Drug Names</b>	UPTRAVI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Cardiologist or pulmonologist. Combination therapy with two or more PAH agents must be prescribed by or in consultation with a pulmonary hypertension specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	VALCHLOR
<b>Drug Names</b>	VALCHLOR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b><i>Prior Authorization Group</i></b>	VECAMYL
<b><i>Drug Names</i></b>	VECAMYL
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	Mild, moderate, and/or labile hypertension. Coronary insufficiency or recent myocardial infarction. Renal insufficiency manifested by rising or elevated BUN level. Uremia. Concurrent use of antibiotics and sulfonamides. Glaucoma. Organic pyloric stenosis. Hypersensitivity to mecamlamine.
<b><i>Required Medical Information</i></b>	Diagnosis of moderately severe to severe essential hypertension or uncomplicated malignant hypertension. Must have documented adequate trials of 2 formulary antihypertensive medications that represent 2 different classes of antihypertensive medications such as an angiotensin receptor blocker (i.e. irbesartan) and a thiazide diuretic (i.e. hydrochlorothiazide) with therapeutic failure.
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	Cardiologist
<b><i>Coverage Duration</i></b>	365 days
<b><i>Other Criteria</i></b>	Not Applicable
<b><i>Prior Authorization Group</i></b>	VELTASSA
<b><i>Drug Names</i></b>	VELTASSA
<b><i>Covered Uses</i></b>	All FDA-approved indications not otherwise excluded from Part D
<b><i>Exclusion Criteria</i></b>	No Exclusion Criteria
<b><i>Required Medical Information</i></b>	Diagnosis. Must have documentation of elevated serum potassium and of target serum potassium level. Must have tried modification of medication regimen to reduce the risk of hyperkalemia if clinically appropriate. Must have trial of, contraindication to, or intolerance to sodium polystyrene sulfonate. For reauth: must have documentation of persistent hyperkalemia and prior reduction in serum potassium levels with Veltassa (patiomer).
<b><i>Age Restrictions</i></b>	No Age Restrictions
<b><i>Prescriber Restrictions</i></b>	No Prescriber Restrictions
<b><i>Coverage Duration</i></b>	Initial: 90 days. Reauth: 365 days.
<b><i>Other Criteria</i></b>	Not Applicable

<b>Prior Authorization Group</b>	VEMLIDY
<b>Drug Names</b>	VEMLIDY
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Hepatitis B Virus Drug Resistance panel showing resistance to prior tx w/ tenofovir
<b>Required Medical Information</b>	Diagnosis. Must have documentation of results of Hep B Virus Drug Resistance panel if previously received antiviral tx regimen for Hep B. Must have documentation of baseline eval and results for following tests: Hep B viral (HBV) DNA load, hepatitis B e antigen (HBeAg), antibody to hepatitis B e antigen (anti-HBe), hepatitis B surface antigen (HBsAg), antibody to hepatitis surface antigen (anti-HBs), liver biopsy (if available), alanine aminotransferase (ALT) level and assay reference range. For reauth: must have doc from prescriber indicating continued benefit from tx, doc of recent HBV DNA level, chart doc of HBV Drug Resistance panel if mbr has evidence of virologic breakthrough (greater than 10-fold increase in serum HBV DNA from nadir during tx in mbr who had initial virologic response), and doc of HBeAg/Anti-HBe/HBsAg/Anti-HBs (for mbrs with HBeAg positive and for mbrs with HBeAg negative not falling under any other indications).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Infectious disease physician, gastroenterologist, hepatologist, or transplant physician
<b>Coverage Duration</b>	Pregnant mbr: 6 months. All others: 365 days until disease progression or clearance.
<b>Other Criteria</b>	Regimens/requirements based upon AASLD Practice Guidelines for Chronic Hepatitis B. For HBeAg+ chronic HBV: must meet 1 ALT criterion (ALT greater than or equal to 2xULN OR evidence of moderate/severe inflammation or signif. fibrosis on biopsy) and have HBV DNA level greater than 20,000 IU/mL. For HBeAg- chronic HBV: must meet 1 ALT criterion (ALT greater than or equal to 2xULN, ALT greater than 1xULN w/ evidence of moderate/severe inflammation or signif. fibrosis on biopsy, ALT less than or equal to ULN w/ ALT increased over time) and 1 HBV DNA criterion (HBV DNA greater than 20,000 IU/mL, HBV DNA greater than 2,000 IU/mL w/ evidence of moderate/severe inflammation or signif. fibrosis on biopsy, HBV DNA less than or equal to 2,000 IU/mL w/ HBV DNA increased over time). For cirrhosis w/ HBV: must have HBV DNA greater than 2,000 IU/mL OR detectable HBV DNA level w/ elevated ALT. For HBV mbr who had liver txfr for HBV or who received solid organ txfr from HBV+ donor: approve regardless of HBV DNA and ALT levels. For HBV carrier who needs immunosuppressive or cytotoxic tx: must be HBsAg+, have planned course of cancer chemotx or immunosuppressive tx. For HBV in mbr currently pregnant to reduce risk of vertical HBV transmission: must be in 3rd trimester of pregnancy and have serum HBV DNA level greater than 10 to the 8th IU/mL. Reauth for HBeAg+: approve x1 year until all of following are met (loss of HBeAg, undetectable serum HBV DNA, completed 6-12 months of additional tx after appearance of anti-HBe). Reauth for HBeAg-: approve x1 yr until loss of HBsAg. Reauth for cirrhosis, for liver txfr for HBV, or for solid organ txfr from HBV+ donor: long-term tx approvable. Reauth for pregnancy: no reauth provided for same pregnancy. Reauth for HBV carriers receiving immunosuppressive or cytotoxic tx: mbr w/ baseline HBV DNA less than 2,000 IU/mL should continue x6 months after completion of chemotx or immunosuppressive tx, mbr w/ baseline HBV

DNA greater than 2,000 IU/mL should continue until reach therapeutic endpoints for immunocompetent HBV as listed above.

<b>Prior Authorization Group</b>	VENCLEXTA
<b>Drug Names</b>	VENCLEXTA, VENCLEXTA STARTING PACK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Members who are on concomitant strong CYP3A4 inhibitors during initiation of therapy.
<b>Required Medical Information</b>	Diagnosis. For chronic lymphocytic leukemia with 17p deletion: must have chart documentation of lab result confirming mutation and trial of at least one prior therapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	VENTAVIS
<b>Drug Names</b>	VENTAVIS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of PAH (WHO Group I) confirmed diagnosis by right heart catheterization. Must have chart documentation of right heart catheterization that indicates the following hemodynamic values: mean pulmonary arterial pressure greater than or equal to 25 mmHg, pulmonary capillary wedge pressure OR left atrial pressure OR left ventricular end-diastolic pressure less than or equal to 15 mmHg, pulmonary vascular resistance greater than 3 Wood units. Must have WHO Functional Class III-IV symptoms. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Pulmonary hypertension specialist, cardiologist, or pulmonologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	B vs. D determination will be made prior to clinical criteria being applied.

<b>Prior Authorization Group</b>	VERSACLOZ
<b>Drug Names</b>	VERSACLOZ
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have an adequate trial and failure of both clozapine tablet AND clozapine orally-disintegrating tablet or have chart documentation of the clinical rationale for why the tablet and orally-disintegrating tablet versions cannot be used.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	VIBERZI
<b>Drug Names</b>	VIBERZI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Alcoholism, alcohol abuse, or addiction. History of pancreatitis or structural disease of the pancreas. Severe hepatic impairment (Child-Pugh Class C). History of chronic or severe constipation or sequelae from constipation or known or suspected mechanical gastrointestinal obstruction.
<b>Required Medical Information</b>	Diagnosis. For diarrhea-predominant irritable bowel syndrome (IBS-D): must have chart documentation of how the diagnosis was confirmed and an adequate trial and failure of loperamide AND an antispasmodic (e.g. dicyclomine) with an inadequate response or significant side effect/toxicity or have a contraindication to these therapies. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Gastroenterologist
<b>Coverage Duration</b>	Initial 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	VIIBRYD
<b>Drug Names</b>	TRINTELLIX, VIIBRYD, VIIBRYD STARTER PACK
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have trial and failure or intolerance to 2 generic antidepressants from SSRI and SNRI classes.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	VIMPAT
<b>Drug Names</b>	VIMPAT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of partial-onset seizures. Must have had an inadequate response or intolerance to 2 generic antiepileptic drugs (e.g. lamotrigine, topiramate, felbamate).
<b>Age Restrictions</b>	Age 17 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a neurologist.
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	VOTRIENT
<b>Drug Names</b>	VOTRIENT
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	VRAYLAR
<b>Drug Names</b>	VRAYLAR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have an adequate trial and failure or an inadequate response or intolerance to 2 generic antipsychotics (e.g., haloperidol, fluphenazine, chlorpromazine, perphenazine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone).
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	XALKORI
<b>Drug Names</b>	XALKORI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming ALK or ROS1 mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	XELJANZ
<b>Drug Names</b>	XELJANZ, XELJANZ XR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Evidence of infection. Use of biologic disease-modifying antirheumatic drug or potent immunosuppressive agent (e.g. azathioprine, cyclosporine) in combination with tofacitinib. Severe hepatic impairment.
<b>Required Medical Information</b>	Diagnosis. Must have negative tuberculosis skin test. Must have moderately to severely active RA. Must have adequate trial and failure of methotrexate with inadequate response (if significant side effects, toxicity, or contraindication to methotrexate, must have adequate trial of hydroxychloroquine, leflunomide, or sulfasalazine). Must have lymphocyte count greater than or equal to 500 cells per cubic mm, ANC greater than or equal to 1000 cells per cubic mm, and Hgb level greater than or equal to 9g/dL. For reauth: must have documentation from the prescriber indicating stabilization or improvement in condition AND recent lymphocyte count, ANC, Hgb, lipid levels, liver function tests. Lymphocyte count, ANC, Hgb, lipid levels, liver function tests must be completed within 3 months of therapy initiation and at regular intervals thereafter.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Rheumatologist
<b>Coverage Duration</b>	Initial: 120 days. Reauth: 365 days.
<b>Other Criteria</b>	Not applicable



<b>Prior Authorization Group</b>	XEOMIN
<b>Drug Names</b>	XEOMIN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For blepharospasm: must have previous treatment with onabotulinumtoxinA. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	XERMELO
<b>Drug Names</b>	XERMELO
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For diarrhea: must be associated with carcinoid syndrome. Must have had a previous trial of a somatostatin analog (e.g., Sandostatin LAR) with failure or inadequate control of symptoms. Must be used in combination with a somatostatin analog. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Oncologist, hematologist, endocrinologist, gastroenterologist or palliative care specialist.
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	XGEVA
<b>Drug Names</b>	XGEVA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Multiple myeloma. Concurrent treatment with denosumab (Prolia).
<b>Required Medical Information</b>	Diagnosis of prevention of skeletal-related events in patients with bone metastases from solid tumors. For giant cell tumor, must have disease that is unresectable or where surgical resection is likely to result in severe morbidity and member must be skeletally mature if less than 18 years of age. For hypercalcemia of malignancy: must have a trial and failure of IV bisphosphonate therapy (i.e. zoledronic acid 4mg/5mL or 4mg/100mL), with failure defined as an albumin-corrected calcium greater than 12.5mg/dL (3.1 mmol/L) despite recent treatment with an IV bisphosphonate.
<b>Age Restrictions</b>	Prevention of skeletal events, hypercalcemia of malignancy: age 18 years or older. Giant Cell Tumor: age 13 years or older.
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 Days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	XIFAXAN
<b>Drug Names</b>	XIFAXAN
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For hepatic encephalopathy: must have trial and failure of lactulose. For diarrhea-predominant irritable bowel syndrome (IBS-D): must have chart documentation of how the diagnosis was confirmed and an adequate trial and failure of loperamide AND an antispasmodic (e.g. dicyclomine) with an inadequate response or significant side effect/toxicity or have a contraindication to these therapies. Reauth for hepatic encephalopathy: must have chart documentation from prescriber indicating improvement in condition. Reauth for IBS-D: must have documentation from prescriber indicating recurrence of IBS-D symptoms after a successful treatment with rifaximin.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Gastroenterologist, hepatologist, or infectious disease specialist
<b>Coverage Duration</b>	Hepatic encephalopathy: 365 Days. IBS-D initial: 14 days. IBS-D reauth: 14 days.
<b>Other Criteria</b>	Criteria only applies to rifaximin 550mg. Criteria does not apply to rifaximin 200mg. For IBS-D: patients who experience a recurrence of symptoms can be retreated up to two times with the same dosage regimen.

<b>Prior Authorization Group</b>	XOLAIR
<b>Drug Names</b>	XOLAIR
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For moderate to severe allergic asthma: must submit patient's weight, must have IgE level greater than or equal to 30 IU/mL AND positive skin or RAST test to perennial aeroallergen. Must have adequate trial of combination therapy with an ICS/LABA (inhaled corticosteroid/long-acting beta-agonist, such as Advair, Breo Ellipta, or Dulera) AND either a LAMA (long-acting muscarinic antagonist, such as Spiriva or Incruse Ellipta) or a leukotriene receptor antagonist (such as montelukast) with inadequate response or significant side effects/toxicities or have a contraindication to these therapies within the last year. Must have asthma symptoms that continue to be uncontrolled on optimized medication therapy regimen (uncontrolled defined as hospitalization for asthma within past year, requirement for oral or parenteral corticosteroids to control exacerbations of asthma on 2 occurrences in the past year, or need for daily corticosteroid with inability to taper off). For chronic idiopathic urticaria: must have chart documentation showing 3-month history of urticaria w/ presence of hives, must have adequate trial of one 2nd generation H1 antihistamine (e.g. levocetirizine) and one leukotriene antagonist (e.g. montelukast) with inadequate responses or significant side effects/toxicity unless contraindicated. For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Persistent asthma: 6 years of age or older. Idiopathic urticaria: 12 years of age or older.
<b>Prescriber Restrictions</b>	Urticaria: allergist, dermatologist, immunologist. Asthma: no prescriber restrictions.
<b>Coverage Duration</b>	Urticaria: 90 days initial, 365 days reauth. Asthma: 365 days.
<b>Other Criteria</b>	For asthma: must follow recommended dosing guidelines based upon weight and IgE level. For urticaria: dosages above 300mg every 4 weeks is not covered.
<b>Prior Authorization Group</b>	XTANDI
<b>Drug Names</b>	XTANDI
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have previous inadequate response or intolerance to abiraterone.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	XYREM
<b>Drug Names</b>	XYREM
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. For cataplexy associated with narcolepsy: must have chart documentation and sleep study to confirm diagnosis. For excessive daytime sleepiness associated with narcolepsy: must have polysomnographic evaluation and chart documentation supporting clinical history of narcolepsy AND must have an adequate trial and failure of 2 central nervous stimulants (e.g. modafinil, armodafinil, amphetamine salts, dextroamphetamine, methylphenidate). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Board-certified sleep specialist, pulmonologist, or neurologist
<b>Coverage Duration</b>	Initial: 90 days. Reauth: 365 days.
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZAVESCA
<b>Drug Names</b>	ZAVESCA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis of mild to moderate Type I Gaucher disease with any of the following: hepatomegaly (defined as liver size greater than or equal to 1.25 times normal), splenomegaly (defined as spleen size greater than 0.2% of body weight), or bone disease (defined as having one of the following: avascular necrosis, Erlenmeyer flask deformity, lytic disease, marrow infiltrations, osteopenia, osteosclerosis, pathological fracture, or radiological evidence of joint deterioration), or bone marrow disease (defined as having anemia or thrombocytopenia). Must not have enzyme replacement therapy as therapeutic option (e.g. allergy/hypersensitivity to ERT, poor venous access, difficulties w/ infusion). For reauth: must have documentation from prescriber indicating improvement in condition.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	By or in consultation with a hematologist or physician who specializes in the treatment of inherited metabolic disorders
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZEJULA
<b>Drug Names</b>	ZEJULA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of complete or partial response to platinum-based chemotherapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZELBORAF
<b>Drug Names</b>	ZELBORAF
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming BRAFV600E mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZINPLAVA
<b>Drug Names</b>	ZINPLAVA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Documentation of confirmed Clostridium difficile infection, as defined by passage of three or more loose stools within 24 hours and positive stool test for toxigenic CDI from a stool sample collected within 7 days of scheduled infusion. Must have high risk of CDI recurrence (65 years or older with a history of CDI in the past 6 months, immunocompromised state, or C. difficile ribotype 027). For reauth: must have documentation from provider indicating rationale for retreatment.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Gastroenterologist or infectious disease physician
<b>Coverage Duration</b>	1 dose per 365 days
<b>Other Criteria</b>	The safety and efficacy of repeat administration of bezlotoxumab in patients with CDI have not been studied.

<b>Prior Authorization Group</b>	ZOLINZA
<b>Drug Names</b>	ZOLINZA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZONTIVITY
<b>Drug Names</b>	ZONTIVITY
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Past history of stroke, transient ischemic attack, or intracranial hemorrhage. Current active pathological bleeding.
<b>Required Medical Information</b>	Past history of myocardial infarction within the past 2 weeks to 12 months or current diagnosis of peripheral artery disease. Must be on concomitant therapy with another antiplatelet agent, such as clopidogrel. Must have documentation of clinical rationale for use of vorapaxar and assessment of member's underlying risk of bleeding to show benefits of vorapaxar would outweigh risk of bleeding.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	Cardiologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZORBTIVE
<b>Drug Names</b>	ZORBTIVE
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Active malignancy
<b>Required Medical Information</b>	Diagnosis of Short Bowel Syndrome (defined as documented malabsorption from small intestines marked by diarrhea, malnutrition, and steatorrhea and that results from resection of the small intestine). Must be receiving adequate nutritional support as determined by prescriber. For reauth: must have documentation from prescriber indicating improvement in condition and clinical rationale for continuation of treatment.
<b>Age Restrictions</b>	Age 18 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	4 weeks
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZORTRESS
<b>Drug Names</b>	ZORTRESS
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Must have undergone solid organ transplant. Must have trial and failure (defined as intolerance to regimen or inability of regimen to prevent rejection at appropriate therapeutic dosing) of anti-rejection regimen containing at least 2 drugs (including cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolate sodium) unless contraindicated.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a transplant specialist
<b>Coverage Duration</b>	365 Days
<b>Other Criteria</b>	B vs. D determination will be made prior to clinical criteria being applied.

<b>Prior Authorization Group</b>	ZOSTAVAX
<b>Drug Names</b>	ZOSTAVAX
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	Age 50 years or older
<b>Prescriber Restrictions</b>	No Prescriber Restrictions
<b>Coverage Duration</b>	1 dose per 365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZURAMPIC
<b>Drug Names</b>	ZURAMPIC
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Severe renal impairment (CrCl less than 30mL/min), end stage renal disease, history of kidney transplant, on concomitant dialysis, tumor lysis syndrome, Lesch-Nyhan syndrome
<b>Required Medical Information</b>	Diagnosis. Must have documentation of symptomatic hyperuricemia and be on concurrent xanthine oxidase inhibitor therapy. Must not have achieved target serum acid levels with xanthine oxidase inhibitor monotherapy defined as a baseline serum uric acid level greater than or equal to 7mg/dL. Must have had at least 2 gout flares in the previous 12 months or a history of at least 1 gout tophus. Must have an adequate trial of combination therapy with a xanthine oxidase inhibitor (e.g. allopurinol or febuxostat) at maximum dosing (800mg/day for allopurinol and 80mg/day for febuxostat) and probenecid with an inadequate response or intolerance to a lower dose of the drug, unless contraindicated. Inadequate response defined as the inability to normalize uric acid to less than 6mg/dL. Must have tried to discontinue or reduce the dose of any medication(s) that may cause hyperuricemia (e.g. thiazide diuretics). For reauth: must have documentation of recent serum uric acid level from prescriber indicating improvement in serum uric acid level while on therapy and must continue to use lesinurad as combination therapy.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	By or in consultation with a Rheumatologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable
<b>Prior Authorization Group</b>	ZYDELIG
<b>Drug Names</b>	ZYDELIG
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable



<b>Prior Authorization Group</b>	ZYKADIA
<b>Drug Names</b>	ZYKADIA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis. Must have chart documentation of lab result confirming ALK mutation.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable

<b>Prior Authorization Group</b>	ZYTIGA
<b>Drug Names</b>	ZYTIGA
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	No Exclusion Criteria
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	No Age Restrictions
<b>Prescriber Restrictions</b>	Oncologist or hematologist
<b>Coverage Duration</b>	365 days
<b>Other Criteria</b>	Not Applicable